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CHAPTER I
INTRODUCTION

The overall objective of this dissertation study was
to ascertain the effects in rats of peripherally administered carboxylated

1,2,3,4-tetrahydroisoquinolines

(THIQs)

on the levels of biogenic amines in certain brain regions.
Furthermore, the principal metabolic routes of specific carboxylated THIQs were elucidated, particularly whether decarboxylation was apparent.

The central nervous system (CNS)

uptake of the THIQs and their major metabolites were measured and related to changes in the levels of the bio- genic
amines.

A.

Background:
Condensation products derived from neurotransmitters

and carbonyl compounds have been detected in the disease
states of alcoholism (1,2), Parkinson's disease(3), and phenylketonuria(4).

Since endogenous levels of these condensa-

tion products have been reported, a new emphasis has been
placed

upon the

pharmacology,

origin,

these compounds.

1

and metabolism

of

2

The condensation products can be separated into two
main groups:
(THBCs).
mines

the THIQs

and the tetrahydro-beta-carbolines

The THIQs are condensation products of phenethyla-

and carbonyl compounds. The THBCs

are condensation

products of indoleamines and carbonyl compounds.

There are

at least four basic sources of the carbonyl compounds which
are available to condense with these neurotransmitters.
first source is acetaldehyde

The

(AcH) which is derived from

ethanol oxidation. A list of several AcH condensation products is found in Table 1.

The second is formaldehyde which

can come from methanol or from the tetrahydrofolate linked
metabolism of one carbon fragments. Table 2 contains a list
of these condensation products.

The third source is pyruvic

acid which is a normal product of glucose metabolism.

The

fourth source is an actual carbonyl metabolite of the neuroamine itself.

Table 3 shows specific examples of this

type of condensation product.

B. The presence of condensation products in mammals.
Acetaldehyde condensation products with dopamine (DA)
and 1-Dopa are presented in Table 1. The dopamine and AcH
condensation product, salsolinol (SAL), has been found to be
in rat brain(S), human cerebrospinal fluid(6), adrenals(7),
and

urine(8).

Its

mono-a-methylated

metabolite

7-0-methyl-SAL (7-M-SAL) has been found in cerebrospinal

Table 1
ACETALDEHYDE CONDENSATION PRODUCTS
Parent Compound

Product
1-Methyl-3-carboxy-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline
(3-CSAL)

Dopamine

1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline
(Salsolinol; Sal)

3-0-Methyl-Dopa

1-Methyl-3-carboxy-6-methoxy-7-hydroxy-1,2,3,4-tetrahydroisoquinoline (6M-3-CSAL)

4-0-Methyl-Dopa

1-Methyl-3-carboxy-6-hydroxy-7-methoxy-1,2,3~4-tetrahydroiso

quinoline (7M-3-CSAL)
Serotonin

1-Methyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline
(1-Methyl-6-hydroxy-THBC)

5-Methoxytryptamine

1-Methyl-6-methoxy-1,2,3,4-tetrahydro-beta-carboline
(1-Methyl-6-Methoxy-THBC)

Table 2
FORMALDEHYDE CONDENSATION PRODUCTS
Parent Compound
1-DOPA

Product
3-Carboxy-norsalsolinol (3-Carboxy-6,7-dihydroxytetrahydroisoquinoline)

Dopamine

Norsalsolinol (6,7-dihydroxy-tetrahydroisoquinoline)

Serotonin

6-Hydroxy-tetrahydronorharmane

5-Methoxytryptamine

6-Methoxy-tetrahydronorharmane

Tetrahydropapaveroline

Tetrahydroprotoberberine (THB)

Table 3

NEUROAMINE DERIVED CONDENSATION PRODUCTS
Parent Amine

Carbonyl Compound

Dopamine

3,4,-dihydroxyphenylacetaldehyde

Dopamine

3,4-dihydroxyphenylpyruvic acid

Dopamine

Phenylacetaldehyde

Dopamine

Phenylpyruvic acid

Product
Tetrahydropapaveroline (THP;
norlaudanosoline)
1-Carboxy-Tetrahydropapaveroline
(1-Carboxy-THP)
3',4'-desoxynorlaudanosoline
3',4'-desoxynorlaudanosoline-1carboxylic acid (DNLCA)

6

fluid (6).

Large amounts of 7-M-SAL have been found in the

urine of alcoholics undergoing detoxification(8).
Barker et al (9) have reported whole rat brain levels
of 6, 7 -dihydroxy-THIQ, the DA and formaldehyde adduct.

It

is speculated that one carbon groups linked to tetrahydrofolate or S-adenosyl methionine are the source of the formaldehyde for this condensation product. The condensation product of DA and pyruvic acid is 1-carboxy-SAL (1-CSAL).
condensation product of

1-Dopa and

AcH is

The

3-carboxy-SAL

(3-CSAL) which is a geometric isomer of 1-CSAL.

The THIQs

derived from formaldehyde, AcH, or pyruvic acid are known as
"simple" THIQs.
"Complex" THIQs are derived from the condensation of
catecholamines
product

of

and

catecholamine

the

derived

condensation

3, 4-dihydroxyphenylacetaldehyde

is

aldehydes.
of

DA

The
and

tetrahydropapaveroline

(THP), which is a probable intermediate in the synthesis of
morphine by the poppy (10-14). The complex THIQ derived from
DA and 3,4-dihydroxyphenylpyruvic acid is 1-carboxy-THP.
THBC

formation

following

ethanol

intake

has

been

reported by several investigators. Mcisaac (15) administered
radiolabeled 5-methoxytryptamine and ethanol or AcH to rats
which had been pretreated with iproniazid and disulfuram. He
found

the

formation

of

urinary

radio labeled

7

6-methoxy-1-methyl-1,2,3,4-THBC

in

the

rats.

Dajani

and

Saheb (16) administered 5-hydroxytryptophan and radiolabeled
ethanol to rats that were treated with inhibitors of monoamine oxidase

(MAO) and aldehyde dehydrogenase inhibitors.

Using thin-layer chromatography as a means of detection the
researchers believe that they found 6-hydroxy-1-methyl-THBC
in 24 hour urine samples from the treated rats.

Dajani and

Saheb failed to rule out the possibility that the spot identified

was

the

formaldehyde

adduct

of

serotonin,

6-hydroxy-THBC, which has been demonstrated to be a normal
constituent of platelets.

Rommelspacher et al.

shown that 6-hydroxy-THBC,

th~

(17) have

derivative of serotonin and

formaldehyde is present in rat brain and platelets and is
excreted by human volunteers ingesting 5-hydroxytryptophan
(5-HTP).

The condensation product of tryptamine and formal-

dehyde, THBC, has been found in platelet rich human plasma
(18).

Bidder et al (19) found material in human platelets

which was
mane),

characterized

which

is

the

as
fully

1-methyl-beta-carboline
aromatised

CHar-

beta-carboline.

3-carboxy-harman has been found in the urine of cows which
were fed silage (20). Evidence has been accumulating showing
that THBC is a normal constituent of both rat brain and
adrenals. The 6-methoxy congener of THBC is readily quantifiable in rat adrenals (21).

8

In

vitro

THBC

formation

is

much

slower

than

6,7-dihydroxy-THIQ in the uncatalyzed process. However, the
ratio of endogenous THBC to the 6, 7 -dihydroxy-THIQ in rat
brain is orders of magnitude greater. This

fact has lead

Barker et al (22) to speculate that the formation of formaldehyde derived THBCs in brain is an enzyme related or catalyzed process.

The pyruvic acid

derived beta-carbolines

have not previously been described in the literature, but
have been detected in a spinal fluid sample taken at death
from a patient suffering from Leigh's disease (23) and in
the spinal fluid of alcoholic monkeys (24).

C. Overview of neuroamine synthesis and metabolism.
The

condensation products

introduced

thus

far

are

derived from the neurotransmitters DA, norepinephrine (NE),
and serotonin

(5-HT).

An

overview

of the substrates and

enzymes involved in the syntheses and metabolism of these
neurotransmitters is necessary for an understanding of the
neuropharmacology and metabolism of these condensation products.
Tyrosine is the essential dietary amino acid necessary
for the synthesis of the catecholamines DA and NE. Tyrosine
is hydroxylated by the enzyme tyrosine hydroxylase yielding
the amino acid L-Dopa. L-Dopa is subsequently decarboxylated

9

by Dopa decarboxylase (DDC) which is also known as Aromatic
Amino Acid Decarboxylase. The product of this reaction is
the neurotransmitter DA. For dopaminergic neurons, this is
the end point of the synthesis scheme. In noradrenergic neurons DA is hydroxylated by the enzyme dopamine-beta-hydroxylase to yield NE (Figure 1).
The metabolism and clearance of DA is accomplished via
the processes of oxidation, a-methylation, and/or conjugation.

Dopamine is oxidized by the enzyme monoamine oxidase

(MAO) to 3,4-dihydroxyphenylacetaldehyde (dopaldehyde).

The

oxidation of a biogenic amine to an acid is a two step process with the enzyme monoamine oxidase (MAO) taking care of
the first step. There are two known isozymes of MAO: MAO A
and MAO B. The preferred substrates for MAO A are 5-HT and
NE. Phenethylamine and benzylamine are the preferred substrates for MAO B. Tryptamine, tyramine, and dopamine are
metabolized by both forms of the enzyme.

Based upon the

redox-status of the cells and the relative affinities of the
substrate for the two subsequent enzymes,

dopaldehyde is

either further oxidized to 3 ,4-dihydroxyphenylacetic acid
(DOPAC) by the enzyme aldehyde dehydrogenase or is reduced
by

the

enzyme

aldehyde

reductase

to

form

3,4-dihydroxyphenethanol (DOPET). Typically though, DOPAC is
the major product of DA oxidation. The catechol moiety of

Figure 1: Catecholamine Synthesis

......
......

12
CAs and DOPAC can be a-methylated by the enzyme catechol-0methyltransferase (COMT) (Figure 2).

1. a-methylation of the catecholamines.

Enzymatic mono-0-methylation of the CAs DOPAC or DOPA
is

performed by

the

enzyme

catechol-0-methyl-transferase

S-Adenosylmethionine

(COMT)

(25) .

donor.

Magnesium is

required for

(SAM)

is

the

methyl

the reaction.

Predomi-

nantly, the hydroxyl group meta- to the alkyl- side chain of
the substrate is a-methylated.
a-Methylation
3-position

of

of

DOPAC

is

the

3-Methoxy-4-hydroxyphenylacetic
HVA).

stereospecific
ring

acid

at

the

and

yields

(Homovanillic

Acid;

a-methylation of DA is also stereoselective at the

3-position

of

the

3-Methoxy-4-hydroxyphenethylamine
lated product

ring

and

(3-M-DA).

can be oxidized by MAO and

produces

This

0-methy-

this product,

3-Methoxy-4-hydroxy-phenyl acetaldehyde is a substrate for
both aldehyde dehydrogenase and aldehyde reductase. Oxidation by aldehyde oxidase predominates yielding HVA.

In the

corpus striatum of the adult rat the nanomole/gram quantities of DA, DOPAC, and HVA are 56.9, 11.6, and 3.8 respectively.

Figure 2: Dopamine Metabolism
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2. Norepinephrine synthesis and metabolism.
As seen earlier, the synthesis of NE requires all of the
enzymes necessary for DA synthesis. Similiarly, the metabolism of NE shares many of the enzymes which oxidize and
a-methylate

DA.

Oxidation

3,4-dihydroxymandelic

of

NE

by

aldehyde.

yields

MAO

of

Reduction

3, 4 -dihydroxymande 1 ic aldehyde by aldehyde reductase produces 3,4-dihydroxyphenylglycol; whereas oxidation by aldehyde oxidase
turn

can

produces 3 ,4-dihydroxymandelic acid which in
be

a-methylated

3-methoxy-4-hydroxy-mandelic acid.

by

COMT

giving

Direct a-methylation of

NE produces normetanephrine which is a substrate for MAO.
of

Oxidation

normetanephrine

produces

3-methoxy-4-hydroxymandelic aldehyde which can be oxidized
by aldehyde oxidase to give 3-methoxy-4-hydroxymandelic acid
or

it

can

be

reduced

by

aldehyde

reductase

to

3-methoxy-4-hydroxyphenylglycol. These pathways of NE metabolism are summarized in Figure 3.
3. Serotonin synthesis and oxidation.
The synthesis of the neurotransmitter 5-HT begins with the
amino acid tryptophan.
enzyme

tryptophan

Tryptophan is hydroxylated by the

hydroxylase

giving

5-hydroxytryptophan

(5-HTP). 5-HTP is decarboxylated to 5-HT by the enzyme

Figure 3: Norepinephrine Metabolism
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aromatic amino acid decarboxylase. 5-HT is oxidized by MAO
yielding 5-hydroxyindole acetaldehyde which is further oxidized to 5-hydroxyindole acetic acid (5-HIAA). Reduction of
5-hydroxyindole

acetaldehyde

would

yeild

5-Hydroxytryptophol.

5-HIAA is the predominant end product

of 5-HT metabolism.(Figure 4).

4. a-methylation of hydroxyindoles.
The hydroxyindoleamine 5-HT can be a-methylated by the
magnesium dependent enzyme indole-0-methyl-transferase. SAM
is the me thy 1 donor.

Most of the brain indole-0-methyl-

transferase is located in the pineal gland.

D. Review of the relevant literature.
The
derived.

condensation products

mentioned

are

neuroamine

Both THIQs and THBCs are taken up into synapto-

somes and stored and thus can be looked upon as "false neurotransmitters".

Cohen has studied the in vivo uptake and

release of THIQs by adrenergic nerves (26).

For this reason

investigators have researched the interactions of these condensation products with the enzymes of synthesis and metabolism of the parent neuroamines.

Figure 4:

Serotonin Metabolism
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Coscia's research group has examine in detail the bioeffects

chemical

of

two

condensation

desoxynorlaudanosolinecarboxylic acid

products:

(DNLCA-the condensa-

tion product of DA and phenylpyruvic acid) and norlaudanosolinecarboxylic acid (NLCA-the condensation product of DA and
3, 4-dihydroxyphenylpyruvic acid) . DNLCA was
potent

inhibitor

of

catecholamine

found to be a

metabolism

in

adrenal

medulla explants whereas NLCA was not (27). They have found
DNLCA to be a good inhibitor of tyrosine hydroxylase (28)
and phenylethanolamine N-methyltransferase (29) whereas NLCA
is not.

Collins and Weiner

(30)

have shown that various

catecholic THIQs are potent in vivo inhibitors of tyrosine
hydroxylase.

3-CSAL was

found to be as potent as NE at

feed-back inhibiting the activity of tyrosine hydroxylase
(the rate limiting enzyme of dopamine synthesis). Neither
SAL nor 3-CSAL have any effect in vitro upon liver dopa
decarboxylase activity
good

substrates

for

(DDC)
COMT

(30).

and

inhibitors of this enzyme (31).

Catecholic THIQs

therefore

are

are

competitive

THP can be biotransformed

by the inclusion of a methyl-bridge to form tetrahydroprotoberberines by rat liver enzymes.

The tetrahydroprotoberbe-

rines are also substrates for COMT (32).

THIQs are in vitro

and in vivo inhibitors of MAO (31,33,34). The norlaudanosoline carboxylic acids (condensation products of DA and phe-

22
nylpyruvic acid or phenylacetaldehyde) are known inhibitors
of adrenal dopamine-beta-hydroxylase(35).
3-CSAL
properties.

possesses

some

interesting

pharmacological

Ethanol narcosis has been shown to be potenti-

ated by the DA and L-dopa derived THIQ 3-CSAL (36). 3-CSAL
has been shown to produce ethanol discrimination in rats
(37) and has been shown to be as potent as Demerol in producing analgesia in the rat (38).
SAL and 7-M-SAL, as mentioned previously, have been
detected in mammals.

The exact source of this brain SAL is

not known. A dietary source is not favored because i.p. SAL
(20 mg/kg i.p. in rats) does not penetrate the blood brain
barrier (39).
The possibility of 3-CSAL being taken up into the central nervous system and subsequently

decarboxylated to SAL

is one of the questions addressed in this dissertation. Carboxylated THIQs have been shown to enter the brain from the
periphery (4) and it is speculated that the uptake is via
the neutral amino acid transport system.
Decarboxylation of 3-CSAL could occur via either an
oxidative or non-oxidative pathway (See Figure 5). Oxidative
decarboxylation

of

3-CSAL

1-methyl-6,7-dihydroxy-dihydroisoquinoline

would

yield
(1-methyl-

6,7-dihydroxy-DHIQ). Non-oxidative decarboxylation of 3-CSAL
would yield SAL.

Figure 5:

Oxidative versus Non-Oxidative
Decarboxylation of 3-CSAL.
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A number of amino acid analogues have been shown to be
taken up by brain tissue and are non-oxidatively decarboxylated, yielding the corresponding neuroamine analogues (See
Figure 6).
dopa

For example, the L-Dopa analogue, alpha-methyl-

(alpha-M-dopa)

given peripherally.

has been found
Acute

in brain tissue when

administration

of

alpha-M-dopa

lead to a brain accumulation of alpha-methyldopamine and
alpha-methylnorepinephrine

(40,41,42).

Brunner et al

gave alpha-M-dopa chronically to rats.

(43)

Again an accumula-

tion of alpha-methyldopamine and alpha-methylnorepinephrine
was seen.

Alpha-methyl-meta-tyrosine (AMMT) given peripher-

ally at a dose of 100 mg/kg intra-peritoneally (i.p.) is
taken up

into the brain where it is

beta-hydroxylated

to

form

metaraminol.

decarboxylated and
Maximal

striatal

brain levels of AMMT were seen at 1 hour after the dose was
given (43).
In contrast to the above examples, alpha-methyl-paratyrosine (AMPT) is not decarboxylated in vivo.

Following

the administration of 80 mg/kg of AMPT to guinea pigs only
AMPT was found in the heart and brain tissues of these animals. The tissues were analyzed for

alpha-methyl-tyramine

and alpha-methyl-norsynephrine content 1,2,4,6 and 8 hours
after the AMPT dose was given.

Of the decarboxylated prod'
ucts 0.2 to 0.3 ug/g could have been detected but were not.

Figure 6:

Examples of Amino Acid Analogues.
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All of the above mentioned examples are compounds having primary amines.

3-CSAL is a cyclized secondary amine.

Pipecolic acid, like 3-CSAL is an imino acid, i.e., it has a
carboxylic acid moiety attached to a ring which contains a
secondary amine. In mouse brain, pipecolic acid is decarboxylated to give piperidine (44,45). It is possible that carboxylated-THIQs might be substrates for this enzyme as well
as for aromatic amino acid decarboxylase.
The possible metabolic routes of 3-CSAL by brain tissue are depicted in Figure 7. It is possible that 3-CSAL
would be a-methylated at either the 6- or 7- position prior
to decarboxylation. 3-CSAL itself was shown to be a poor
inhibitor of DDC and therefore a poor substrate (30). However 6-M-3-CSAL and 7-M-3-CSAL might well be suitable substrates for DDC producing 6-M-SAL and 7-M-SAL respectively.

Figure 7:

Some Possible Metabolic Routes for 3-CSAL
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In order to document the actual metabolism of 3-CSAL
by rats in vivo it was necessary to synthesize de novo all
the possible metabolites of 3-CSAL seen in Figure 7.

Sec-

ondly, the weak cation-exchange resin Bio-Rex 70 (46,47) was
utilized to isolate 3-CSAL and its possible metabolites as
well

as

the neurotransmitters and their metabolites

tissue samples.
Dowex 50,
isolate

Although the strong cation-exchange resin

X-4 has been used by a number of researchers to

the

neurotransmitters

49,50,51,52,53,54),
used

in

from

a

typically

fluorometric

tightly to Dowex

and their
these

assay.

metabolites

eluents

Since the

were

(48,

directly

compounds

bind

(especially the THIQs), either large vol-

umes of acid or high molar concentrations of the acids were
necessary for elution.
For gas chromatography and HPLC,
concentrate
eluents,

the

substantial

Therefore

Upon

samples.

Bio-Rex

70

oxidation

it is necessary to

lyophilization
of

the

samples

of

these

is

seen.

is the preferred preparative

column

since small volumes of dilute acid is sufficient for isolation of the amine fraction with good recovery upon lyophilization.
Appropriate
electrochemical
resolution

methods

detection

of

liquid

were

also

and quantitation

of

all

chromatography
developed
of

the

with

to provide

compounds

of

32
interest within a reasonable time-frame.

Chromatographic

methods in the literature describe separation of the catecholamines by
HPLC

by

HPLC with cation-exchange

reverse-phase

(59, 60,61, 62,63, 64).

chromatography

(55 ,56 ,57 ,58)
with

or

ion-pairing

These methods were not utilized for

the measurement of the biogenic amines and their respective
acid metabolites in the tissues samples for this dissertation for two reasons: 1) NE and 3-CSAL consistently co-chromatographed using the buffers described in the literature
and 2) 5-HT' s retention time was so great as to severely
decrease both peak height and sample throughput.

E. Tissue samples analyzed and experimental strategy.
Three brain regions were chosen to be analyzed for the
metabolism of and effects of 3-CSAL: the hypothalamus which
is rich in NE, 5-HT, and contains DA innervation; the corpus
striatum which is nearly devoid of NE terminals but has the
highest DA content of any brain region and has modest 5-HT
innervation

from the

raphe nucleus;

and the

hippocampus

which has moderate levels of NE and 5-HT but practically no
DA terminals (65,66).
The levels of the THIQs in these individual tissues
will be related to the type of innervation of the individual
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tissues, and to the levels of the neurotransmitters NE, DA,

s-HT and their respective acid metabolites.

If changes in

neurotransmitter content were produced by 3-CSAL, they could
be due to release of neurotransmitters from storage sites
(displacement) or due to an inhibition of the respective
neurotransmitter's synthesis or clearance.

Experiments in

which rats are pretreated with an inhibitor of dopa decarboxylase would reveal

if changes

in the neurotransmitter

levels was due to increased synthesis of 5-HT, i.e. precursor amino acids would accumulate to a greater extent in the
3-CSAL treated animals versus the appropriate controls. Two
well characterized inhibitors of DDC are R04-4602 which in
low doses (50 mg/kg) only inhibits DDC peripherally (however

BOO mg/kg provides total DDC inhibition) (67,68,69,70) and
NSD-1015

which

provides

total

(peripheral

and

inhibition of DDC when given in low doses (71,72).

central)
A car-

boxylated THIQ dose of 50 mg/kg for one hour prior to sacrifice was chosen based on the results reported by the investigators

who

gave

rats

i.p.

analogues described earlier.

doses

of

the

amino

acid

Typically, maximal brain lev-

els of the injected drug were seen at the one hour time
point.
Although 3-CSAL is

catecholamine derived and it

is

most likely that its neurochemical effects would be upon the
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catecholamines, its effects upon 5 -HT and 5 -HIAA levels in
the various

tissues were determined,

predicated upon the

fact that AMMT, which is also catecholamine derived has been
shown to lower brain 5-HT (73).
It was decided to compare aspects of the metabolism
and neurochemical effects of 3-CSAL to two other carboxylated-THIQs,

1-CSAL

and

transmitters (Figure 8).

1-carboxy-THP,

on

regional

neuro-

These THIQs are representative of

two other alkaloid types, the first being the condensation
product of

DA

and pyruvic

acid.

This

compound

could be

formed in diseases in which pyruvic acid accumulates, such
as subacute necrotizing encephalitis (Leigh's Disease)(74).
The second is formed in the disease state of Phenylketonuria
(PKU).

F. HPLC with electrochemical detection.
High performance liquid chromatography with electrochemical detection (HPLC/EC) is the preferred technique for
measuring the compounds which have been discussed thus far.
HPLC/EC was first described by Kissinger et al in 1973 (75).
The electrochemical

detector maintains

a

voltage applied

across a 1 microliter volume flow cell through which

Figure 8:

Carboxylated THIQs Studied.

3-CSAL

1-C SAL

•

OH

1- COOH

THP
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the column eluant passes. For oxidative HPLC/EC, a positive
voltage is applied across the flow cell and a standing electron current is maintained. This is known as the background
current. When an oxidizable compound passes into the detector cell, the compound gains or absorbs electrons

(oxida-

tion), which results in a corresponding drop in the current
reaching the cathode of the detector. A potentiometer measures the drop in the current across the cell and compares it
to a reference voltage set up by a silver/silver chloride
reference cell. The potentiometer then converts this drop in
current to a voltage output which in turn drives the chart
recorder or integrator.
The detector response for individual compounds relies
heavily upon several parameters: the intrinsic ease of oxidation of the individual compounds; the voltage applied to
the cell; the amount of time the compound spends in contact
with the detector; and the ability of the eluting buffer to
conduct current and transfer charge.
The catecholamines,
acid metabolites

are

5 -HT, plus

among

the

their precursors and

compounds with

response to electrochemical detection.

the

best

Similiarly, the con-

densation products derived from these compounds are easily
detected by HPLC/EC.

The magnitude of the voltage applied

across the detector cell influences the detector response.
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For each compound there is a specific voltage which gives
The HPLC/EC is an inefficient

maximum detector response.

detector using a flow rate of 1 ml/min,

in that approxi-

mately only 10% of the sample is irreversibly oxidized and
yet the signal to noise ratio for the detector is very large
thereby permitting great sensitivity.

Much of the lack of

efficiency is due to the geometry of the detector (lack of a
large surface area), but equally important is the amount of
time that the compound is in the detector. If the oxidation
is a slow process, then increased time spent in the detector
would permit increased amount of sample oxidized and therefore detected. Also, of great consideration is the intrinsic
electrical conductivity of the eluting buffer.
must

reach

the

compound

in

order

to

be

Electrons

captured.

The

citrate/phosphate buffers introduced by Kissinger are very
electrochemically active in the sense that they conduct current

without

generating

(intrinsic resistivity)

an

appreciable

background

noise

at the voltages used for optimal

measurement of the compounds of interest.

It is interesting

to note that a 0.1 M sodium phosphate monobasic buffer provides a good medium for electrochemical detection whereas a
0.1 M ammonium phosphate monobasic buffer,

pH 5. 0 yields

poor sensitivity for the compounds of interest as the background noise by far exceeds the signal reaching the detector

when this buffer is used.

Therefore it is critical that the

buffer selected for any chromatography with electrochemical
detection needs to both accomplish resolution of the compounds chromatographed as well as provide suitable conductivity for efficient electrochemical detection.

CHAPTER II
MATERIALS AND METHODS

A.

Materials.
Dopamine HCl salt (Sigma)
Dopamine HBr salt (Aldrich)
Norepinephrine HCl salt (Sigma)
Epinephrine HCl salt (Sigma)
3,4-dihydroxybenzylamine HBr salt (Aldrich)
Normetanephrine HCl salt (Sigma)
Metanephrine HCl salt (Sigma)
Vanilmandelic Acid (Sigma)
Homovanillic Acid (Sigma)
3,4-Dihydroxyphenylacetic acid (DOPAC) (Sigma)
Serotonin Creatinine Sulfate Complex (5-HT) (Sigma)
5-Hydroxyindole acetic acid (5-HIAA) (Sigma)
3-D-methyl dopamine (Sigma)
Salsolinol HCl (de novo)
6-0-methyl-Salsolinol (de novo )
7-0-methyl-Salsolinol (de novo)
4-0-methyl-dopamine (Calbiochem)
3-CSAL (de novo)
L-Dopa (Sigma)
40
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Acetaldehyde AR (Fischer)
4-0-methyl-Dopa (gift:

John Daly, NIH)

3-D-methyl-Dopa (Sigma)
Pyruvic acid (Sigma)
Sodium phosphate monobasic monohydrate (Baker)
Sodium phosphate dibasic heptahydrate (Baker)
Sodium phosphate dibasic anhydrous (Baker)
EDTA (Fisher)
Ammonium phosphate monobasic (Baker)
Ammonium phosphate dibasic (Fisher)
1-Heptane sulfonic acid (Kodak)
Methanol (Kodak)
Ethyl acetate (Fisher)
Acetone (Baker)
Ammonium hydroxide concentrate (Scientific Products)
Hydrochloric acid AR (Scientific Products)
Perchloric acid, 60% reagent (Baker)
Nitric Acid concentrated (Scientific Products)
Acetic Acid, glacial (Baker)
n-Butanol (Baker)
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B.

Equipment

Aminco-Bowman Spectrophotofluorometer with
Ratio Photometer
Serval RC2 ultracentrifuge
FTS Flexi-Dry Lyophilizer
LC-2A Potentiometer
TL-5A Amperometric Detector
LC-19 Silver-Silver Chloride reference electrode
Bio Rad ODS-10 micron 250mm x 4mm analytical column
Model SR-204 Heath Single Pen Chart Recorder
TI-55 Calculator
Partisil-SCX 10 micron Strong Cation Exchange
250 x 4 mm analytical column
Bio-Rex 70 Weak Cation Exchange Resin
Isolab Minico1umns
Columns made from Pasteur pipets
plugged with glass wool
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C.
1.

Methods

The Separation of the Neurotransmitter
Metabolites Using Bio-Rex 70.
a.

Properties of the Resin.

Bio-Rex 70 is a polyacrylic resin whose active moiety
is a carboxylic acid functional group. The carboxylic acid
functional

group will

form

a

salt

linkage

with primary

amines only within a narrow pH range of 5.5-6.0. At this pH
the acid moiety of the resin is unprotonated and therefore
can form a salt linkage with a cationic species(76).
The weak cation-exchange characteristic of this resin
permits the separation of

thre~

classes of functional groups

of the molecules relative to the neurotransmitters:
neutral

metabolites;

the

precursor amino

acids;

acid/
and

the

amines. The acid metabolites of the neurotransmitters do not
bind to the resin at all at pH 5. 5 to 6. 0, and they are
removed in the void volume and water wash.

There is a cou-

lombic repulsion between the acid metabolites and the binding sites of the resin.

The amphoteric molecules such as

the amino acids bind to the res in, but only weakly.

The

amine moiety of the amino acid forms the salt linkage, but
the presence of the acid moiety lessens the strength of that
bond; they are eluted with 0.02 M sodium phosphate buffer,
pH 6.5.

The neuroamines themselves bind best to the resin

(46) and they are eluted with acid.
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b.

Preparation of the Resin.

Bio-Rex 70, 200-400 mesh,

sodium form was purchased

from Bio-Rad Laboratories (Richmond, CA). Resin was added to
a one-liter beaker, enough to occupy the 200 ml mark. The
resin was

then suspended in

distilled water.

The

larger

resin beads settled to the bottom of the beaker. The finer
particles, still in suspension, were decanted off with the
water. This process was repeated until the supernatant is
clear, i.e. free of fine particles. The sizing of the resin
ensures that the flow rates of the columns made from the
resin will be more uniform and faster.
The resin was then stirred in 3 N ammonium hydroxide
and allowed to settle. The resin was then washed with distilled water until the supernatant was neutral. Then the
resin was stirred in 3 N hydrochloric acid (HCl).

Again, it

was washed with distilled water until the supernatant was
neutral. Afterwards,

3 N sodium hydroxide was used to gen-

erate the sodium form of the resin. The resin was washed
then with distilled water until the pH of the supernatant
was less than 9.0.
Subsequently, the resin was washed with 0.1 M sodium
phosphate buffer, pH 6.5, containing 0.1% EDTA. The washing
was continued until the pH of the supernatant was 6.5. The
pH of the supernatant was checked the next day to ensure
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that it remained at 6.5. If it had increased, then the resin
was washed with fresh buffer. This would be repeated daily
until

the

pH

of

the supernatant

remained

at

6. 5.

This

exhaustive washing gave better blanks for the fluorescent
and chromatographic assays.

Interferring substances, which

otherwise would elute with the samples, were removed.
c.

Column Preparation-The Fluorescent Studies.

Pasteur pipets were used to form mini-columns.

Glass

wool plugs were placed into the bottoms of the pipets and
enough resin was added to form a 3 em bed. Out of the population of pipet-columns

thus

formed,

the ones with flow

rates of plus or minus one standard deviation of the mean
were chosen to be used in the experiments. Since the resin
was stored in 0.1 M phosphate buffer, pH 6. 5, the columns
were rinsed with 25 ml distilled water prior to use.
d.

Column Preparation-The HPLC Studies.

Isolab Quik-Sep Columns were used in some of the HPLC
studies. They were filled with 500 ul of resin. The resin
filled columns were rinsed with 25 ml distilled water prior
to using.
2.

Reagents.
Alkaline ascorbate: 100 mg L-ascorbic acid (Sigma) was

dissolved in 1.0 ml of quartz-distilled water and 50 ml of
10 N sodium hydroxide was added.
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Alkaline sulfite:

1. 25 g

sodium sulfate (Baker) was

dissolved in 5 ml of quartz-distilled water, and 45 ml of 5
N sodium hydroxide was added.
Sodium periodate: 0.5% (w/v) sodium periodate (Baker)
in quartz-distilled water.
Perchloric acid: 0.4 N (Baker)
Potassium carbonate:1 N (Baker)
Potassium ferricyanide:

0.25% (w/v) (Baker)

3. Buffers.
0.1 M phosphate,

0.1~~DTA,

pH 6.5: 8.28 g sodium phos-

phate monobasic, monohydrate; 5.68 g Sodium phosphate dibasic, anhydrous; 10 ml 10% EDTA per liter of quartz distilled
water.
0. 02 M phosphate,
phosphate monobasic,
dibasic, anhydrous,

0. 2% EDTA, pH 6. 5:

monohydrate,
20 ml

1. 66 g sodium

1.14 g sodium phosphate

10% EDTA per liter quartz-dis-

tilled water.
0. 5 M phosphate,

pH 7. 0

(Norepinephrine determina-

tion): 70.98 g sodium phosphate dibasic, anhydrous per liter
of quartz-distilled water; 68.04 g potassium phosphate monobasic, anhydrous per liter of quartz-distilled water. 61.0
ml sodium phosphate solution was mixed with 39.0 ml of the
potassium phosphate solution.
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0.5 M phosphate, pH 7.0 (dopamine determination): A 1
M solution of potassium phosphate monobasic, anhydrous was
adjusted to pH 7. 0 with 1 N sodium hydroxide and diluted
with quartz-distilled water to a concentration of 0.5 M.
Citrate 0.5 M, pH 4.0: A 1 M citric acid solution was
adjusted to pH 4. 0 with sodium hydroxide and diluted with
quartz-distilled water to a concentration of 0.5 M.
4.

Tissue Sample Preparation.
Animals were sacrificed by a blow on the head and

decapitation.

Brain regions were dissected out as per Iver-

son and Glowinski (77,78), immediately put into weigh boats
and placed upon blocks of dry-ice.

Brain region masses were

determined using a 5-point Mettler Balance.
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5.

Extraction of the Biogenic Amines, THIQs and Their
Metabolites from Tissues.
The samples were extracted either with perchloric acid

or with ice-cold ethanol.
Acid extraction:

The samples were placed into dispo-

sable test tubes (16 x 100 mm; SP-T1285-6) which contained
500 ul ice-cold 0. 4 N perchloric acid

(O .1% EDTA).

Each

sample was homogenized at maximal speed with a Tissue-Tek
Homogenizer for 30 seconds. The homogenate was transferred
to a Serval centrifuge tube. The homogenizer probe and dispo
test tube were rinsed three times with the perchloric acid
solution, and the rinses were added to the Serval centrifuge
tube.

The sample tubes were kept on ice throughout the pro-

cedure. The tubes were then transferred to the Serval RC-2
refrigerated centrifuge and spun for 15 minutes at 18,000
rpm (4 C).

The supernatant was pipetted into 20 ml capacity

scintillation vials.

One of the control samples was split.

To one half, 100 ng of each of the compounds of interest was
added. To the other half, distilled water was added. This
constituted a control for recovery after homogenization.
The

pH

of

the

adjusted to 5.5-6.0.

perchloric

acid

supernatants

were

Initially, this was done coarsely to a

pH of approximately 4.0, using 2.0 N potassium hydroxide and
then carefully to pH 5.5-6.0 with 0.2 N potassium hydroxide.
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Since this was largely an ionic equilibrium, care had to be
taken not to expose the sample to harsh alkaline conditions
which could oxidize the compounds investigated. Perchlorate
ions in excess of those necessary to precipitate the proteins were removed from solution by the potassium ions. The
two species readily formed the sparingly soluble potassium
perchlorate salt.

It is very important to remove as much of

the potassium perchlorate from solution as possibe. At 0
degrees centigrade the solubility of potasium perchlorate is
0. 75 g/ 100 ml; whereas at 25 degrees centigrade 1. 6 g of
the salt can be dissolved in 100 ml. Failure to remove the
potasium perchlorate

in solution at

25 degrees or

at 4

degrees will result in displacement of members of the amino
acid fraction into the void volume.

Precipitation of this

salt was enhanced by placing the scintillation vials of pH
adjusted solutions on a block of dry-ice. As soon as the
solutions froze completely, they were removed from the dryice and allowed to thaw. The clear solution was pipetted
away from the precipitate and applied to the pasteur-pipette
or Isolab columns.
The effluent, plus a 1.0 ml distilled water wash, was
collected and labelled the primary eluent. This fraction was
frozen

and

lyophylized

prior to

analysis.

The

precursor

amino acids were eluted using 1. 5 ml of 0. 02 M phosphate

50

buffer followed with 1.0 ml distilled water. This fraction
was

labelled

degrees

the amino acid

fraction and frozen

centrigrade until the fraction was

at

-20

analyzed.

The

amines were e 1uted with 1. 5 ml of 0. 5 N acetic acid. This
fraction was labelled the amines and frozen at -20 degrees
centrigrade until analyzed (Figure 9).

Column blanks were

derived from a column which had no tissue applied to it, but
was

otherwise

processed

blanks were generated:

as

described

above.

Thus

three

a primary eluent fraction blank, an

amino acid fraction blank, and an amine fraction blank.
Ethanol extraction: The tissue samples were homogenized in 75% ice-cold ethanol (.5 ml/g tissue). After homogenization and centrifugation as described above, the supernatants

were

diluted

1: 1

with

distilled

water.

separation of the component fractions was necessary,

When
the

diluted ethanol extract was applied to Bio-Rex 70 columns.
When chromatography with resolution of all of the compounds
of interest was possible, the diluted ethanol solution was
first lyophilized and then reconstituted with 0.1 N HCl and
directly injected into the high performance liquid chromatograph.

Figure 9:

Bio-Rex 70 Preparative Column Chromatography
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6.

Fluorometric analyses.
The fluorometric analyses for the amines were adapted

from those employed by Holman et al (47).
a.

Serotonin.

A 500 ul aliquot of the amine fraction was placed into
a disposable test tube.
added.

To this

150 ul of 12 N HCl was

The mixture was vortexed and the fluorescence was

then read at an activation wavelength of 278 nm and an emissian wavelength of

545 nm.

External standards,

reagent

blanks and column amine fraction blanks were run each time
with the samples. Stock solutions were made up in 3 N HCL
and serially diluted with 3 N HCl to form the standards and
the standard curve.
b.

Norepinephrine:

formation of the

trihydroxy-indole chromophore.
To 200 ul of the 0.5 N Acetic acid eluent, 200 ul of
0.5 M sodium phosphate buffer, pH 7.0, was added. The pH was
adjusted to a pH of 6.5-7.0, with approximately 600 ul of 1
M potassium carbonate. An addition of 20 ul of a fresh solution of 0.25% potassium ferric cyanide was placed into the
tube; one minute later 200 ul of freshly prepared alkaline
ascorbate was added; at 15-30 second thereafter, 600 ul of
distilled water was added. The samples had to be measured
within 3 to 6 minutes after the initiation of oxidation. The
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fluorescence was monitored at

an excitation wavelength of

336 nm and an emission wavelength of 502 nm. A column amine
fraction blank was run at the same time.
c.

Dopamine assay:

generation of the

dihydroxyindole chromophore.
To 200 ul of the 0.5 N acetic acid amine fraction, 100
ul of pH 7.0 sodium phosphate buffer was added. The pH was
adjusted to 6.5-7.0 with 1 N potassium carbonate. Oxidation
was initiated with 100 ul of a 0.5% (w/v) solution of sodium
periodate. One minute later, 300 ul of the alkaline sulfite
solution was added. Both the periodate and sulfite solutions
were made up immediately before use. A 100 ul volume of 0. 5
M sodium phosphate buffer, pH 4.0 was added, followed by 170
ul of 3 N phosphoric acid. The fluorescence was measured
within ten minutes at an excitation wavelength of 316 nm and
an

emission wavelength

of

370

nm.

Stock

solutions

and

serial dilutions were made up with 0.5 N acetic acid. A column amine fraction blank was run at the same time.
d. 5-hydroxy-indole acetic acid.
The native fluorescence of 5-HIAA was measured in 3 N
HCl.

The

lyophylized primary eluents

with 500 ul of 3 N HCl.

were reconstituted

The excitation wavelength was 290

nm with an emission wavelength of 545 nm. Standard solutions
were made of 5-HIAA at a concentration of 1 mg/ml in dis-
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tilled water serially diluted with 3 N HCl. A column blank
primary eluant fraction was run at the same time.
e.

Tryptophan analysis.

The tryptophan assay was adapted from the Bloxam and
Warren (79) modification of the Dewey and Denkla method (80)
utilizing an excitation wavelength of 373 nm and an emission
wavelength of 452 nm.

The assay was linear in sensitivity

from 8 ng-4 ug. Tryptophan was converted to the fluorescent
species, norharman.

Glass-stoppered test tubes, which were

scrupulously cleaned weekly with concentrated nitric acid
overnight, were used in the assay.
Two ml of 10% trichloroacetic acid (w/v) was placed
into the glass-stoppered test tube. A 100 ul aliquot from
the amino acid fraction was added and the tube was vortexed.
Then 100 ul of 0. 0061 M ferric chloride in 10% trichloracetic acid was added. The test tube was placed into rapidly
boiling water for one hour. Turbidity developed in some of
the test tubes.

These samples scattered the

incident fluorescent beam.

light of the

To overcome this,

the samples

were centrifuged in a clinical centrifuge at 2,000 rpm for
five minutes. The clarified samples were then read in the
spectrophotofluorometer. A column amino acid fraction blank
was run at the same time.

Neither 3-CSAL nor SAL interfered

with any of the fluorescence analyses described.
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7.

HPLC chromatography.

Quantitation of the compounds of interest was accomplished by means of an electrochemical detector (Bioanalytical Systems) and was based on peak heights.

Kissinger et al

have recently published a comprehensive review of neurochemical applications
(81).

of HPLC with

electrochemical detection

For this dissertation, two types of HPLC columns were

utilized in the quantitation of the compounds of interest: a
reverse-phase column using an ion suppression buffer and a
strong cation exchange column.
Reverse-phase /ion suppression chromatography operates
on the basis of relative hydrophobicity of the compounds of
interest in the mobile phase used.
the

biogenic

amines

and

their

The ionic character of

acid

metabolites

can

be

expressed or suppressed depending upon the pH of the mobile
phase.

The ionic strength of the mobile phase is not the

predominant factor in this system. The retention times for
all of the compounds of interest from a 0.1 M Sodium Phosphate buffer (pH 5.0), with 1 mM EDTA are given in Table 4.
The 0-methyl-SALs were not resolved and had relatively long
retention times in this

system (22.8 min.).

Furthermore,

the acid metabolites eluted in the same vicinity.
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Table 4
HPLC RETENTION TIMES OF COMPOUNDS USING
A BioSil ODS 10 Column and 0.1 M Sodium Phosphate
Monobasic Monohydrate, 1.0 mM EDTA, pH 5.0.
COMPOUND

RETENTION TIME (MIN)

Norepinephrine
DHBA
Dopamine
DOPAC
5-HT
5-HIAA
HVA

1.9
3.9
5.2
6.8
13.6
17.6
20.1

Sal
6-M-Sal
7-M-Sal

8.4
22.8
22.8

1-CSAL
6-M-1-CSAL
7-M-1-CSAL

4.0
12.8
16.2

3-CSAL
6-M-3-CSAL
7-M-3-CSAL

4.4
14.4
16.0

58
The use of a strong cation-exchange HPLC column (Partisil-SCX)
7-M-SALs,

provided

not

only

resolution

of

the

6-

and

but also isolated these compounds away from the

acid metabolites which now elute in the

solvent front

in

this system. The ionic strength and pH chosen to chromatograph these compounds provided optimal response and elution
times while preserving resolution of these compounds.
Since chromatography of the compounds was done utilizing a variety of parameters, for all cases, representative
chromatograms show the conditions utilized.
that

only

trace

amounts of

decarboxylated products

have been present in the samples.
sensitivity

were

It is possible

determined

for

might

Therefore, the limits of
SAL,

7-0-M-SAL,

and

6-0-M-SAL. The detector signal at twice background was 0.2
nanoamps.

A plot of nanoamps versus nanograms was done for

each of the compounds.

The nanogram value at 0.2 nanoamps

represents the limit of sensitivity for each of these compounds. The limits of detection were 2.0 ng/ml for SAL, 3.56
ng/ml for 6-0-M

-SAL,

and 5. 88 ng/ml

7-0-M-SAL by cation

exchange HPLC with electrochemical detection. When reversephase HPLC with electrochemical detection was employed, the
limits

of

detection

were

1.02

6-0-M-SAL, and 3.0 ng/ml 7-0-M-SAL.

ng/ml

SAL,

1.82

ng/ml
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The student's t-test was used in all of the statistical analyses. A p value of < 0.05 was considered to be statistically significant.

CHAPTER III

EXPERIMENTAL SECTION
All of the subjects were male Sprague-Dawley rats purchased from King Animal Laboratories (Madison, Wise.).

All

of the experiments were initiated at 3 pm Central Standard
Time and the route of administration of the drug in all
instances was

intraperitoneal injection of the drug in a

sterile saline vehicle.
A.

Fluorescent Studies.
1.

Acute 50 mg/kg 3-CSAL.

Sprague-Dawley rats

(300-400g)

received a

50 mg/kg

dose of 3-CSAL in a sterile saline vehicle. Saline alone was
given to the control group. One hour later the animals were
sacrificed. The corpus striatum and the hypothalamus were
taken from each animal. Dopamine and norepinephrine levels
were measured by fluorescence after being isolated using
Bio-Rex 70 columns.
2.

Acute 50 mg/kg 3-CSAL in animals
pretreated with a peripheral
decarboxylase inhibitor,
R04-4602 (Benserazide).
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Sprague-Dawley rats (300-400g) were pretreated with a
peripheral dopa decarboxylase inhibitor, R04-4602, at a dose
of 50 mg/kg.

One hour later a 50 mg/kg dose of 3-CSAL was

given to the experimental group. The control group received
saline alone. Corpus striatum and hypothalamic tissues were
assayed.

Dopamine

and norepinephrine were

isolated using

Bio-Rex 70 and measured fluorescently.
3. Acute 50 mg/kg 3-CSAL in animals
pretreated with a total
decarboxylase inhibitor.
Male Sprague-Dawley rats

(300-400g)

were pretreated

with NSD-1015 at a dose of 100 mg/kg which provided total
dopa decarboxylase inhibition.

The NSD-1015 was

adminis-

tered in a sterile saline vehicle to both the experimental
and the control groups.

One hour

later, the experimental

group received a 50 mg/kg dose of 3-CSAL dose in a sterile
saline

vehicle.

The

control

group

received

the

sterile

saline alone. One hour subsequent to this, both groups of
animals were sacrificed. Corpus striatum and hypothalamic
tissues were

evaluated.

Dopamine and norepinephrine were

measured by the fluorescent technique after being isolated
using Bio-Rex 70.
4.

Dose-response study with 3-CSAL.
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Doses of 50,150, or 400 mg/kg were given to groups of
male

Sprague-Dawley

rats

received saline alone.

(210-270g).

Control

animals

One hour later the .animals were sac-

rificed. Dopamine, norepinephrine, and serotonin levels were
measured in corpus

striatum and hypothalamic tissue.

The

neurotransmitters were isolated using Bio-Rex 70 and measured by fluorescence.
5.

Chronic 3-CSAL (50 mg/kg i.p.).

A 50 mg/kg dose of 3-CSAL was given to male SpragueDawley rats (112-152g) every eight hours for a total of five
days.

At the same times, the control group received sterile

saline. One hour after the last injection, the animals were
sacrificed.
assayed.

Corpus

Dopamine,

striatum and hypothalamic
norepinephrine,

serotonin,

tissue were
tryptophan,

and 5-hydroxyindole acetic acid were measured fluorometrically after being isolated using Bio-Rex 70.
B.

Animal HPLC studies.
1.

Rats

100 MG/KG 3-CSAL for 30 Minutes.
(295-340g; 90 days old) were given a 100 mg/kg

dose of 3-CSAL. Two animals were sacrificed at 15 minutes
after the dose was given, and four were sacrificed at the 30
minute time point. Blood, caudate, and hypothalamic tissues
were taken for analysis. The samples were fractionated using
Bio-Rex 70 ,

lyophilized and stored at -20 degrees centi-

grade until assayed by HPLC.
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2.

A Single Dose Time Study.

Male Sprague-Dawley rats (250-350g; 90 days old) were
given 3-CSAL

(50 mg/kg).

The control group was

with the sterile saline alone.

injected

At time intervals of one

hour, three hours, eight hours and twenty-four hours rats
were

sacrificed.

The

tissues

were

ethanol

extracted.

Extracts were lyophilized, reconstituted in 0.01 N HCl, and
directly injected into the high performance liquid chromatograph.

The corpus striatum was analyzed for its content of

3-CSAL and its a-methylated metabolites.

Dopamine, DOPAC,

HVA, serotonin, and 5-HIAA were also measured in this tissue.

THIQ content was also determined in blood, heart and

liver.
3.

The effect of 3-CSAL on 5-HT synthesis.

Male Sprague-Dawley rats (214-407g; 2-10 months) were
pretreated with 800 mg/kg R04-4602 for one hour. The control
group was

then given sterile saline and the experimental

group received 50 mg/kg 3-CSAL. One hour later the animals
were sacrificed. Striatal tissues were extracted with icecold ethanol and placed on Bio-Rex 70 columns. The precursor
amino

acid

fraction

was

collected

and

analyzed

5-hydroxytryptophan content.
4.

The relationship of age of the rat
to 3-CSAL's effect upon serotonin.
a.

Old rats.

for
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Male Sprague-Dawley rats (392-455g; 10-12 months) were
given 3-CSAL (50 mg/kg).

The control group received sterile

saline alone. Eight hours later the animals were sacrificed.
Hypothalamic and striatal tissues were dissected and ethanol
extracted. Extracts were lypholized, reconstituted in 0.01 N
HC 1 and directly injected into the high performance liquid
chromatograph.
b.

Young rats.

Young rats

(94-105g; 35 days old) were given 3-CSAL

(50 mg/kg i.p.).

The control group received the sterile

saline vehicle alone. Control and experimental animals were
sacrificed at 4 and 8 hours after the injections. The striatum and hypothalamus were dissected, extracted with ice-cold
ethanol, and placed upon Bio-Rex 70 to isolate the amine
fraction. DA and 5-HT content were determined.

5.
The

R04-4602 and 3-CSAL.
peripheral decarboxylase

inhibitor,

benserazide

(R04-4602; 50 mg/kg), was given to male Sprague-Dawley rats
(196-205g; 50 days old) one hour before they were given a 50
mg/kg dose of 3-CSAL. The animals were sacrificed one hour
after the 3-CSAL was given. Control rats received a 50 mg/kg
dose of R04-4602 and were sacrificed two hours later.

Stri-

atal, hypothalamic, and hippocampal samples were extracted
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with 75% ethanol and analyzed by HPLC for dopamine, serotonin, DOPAC, HVA, and 5-HIAA.

6.

NSD-1015 and 3-CSAL.

Male Sprague-Dawley rats (200-214g; 52 days old) were
pretreated with NSD-1015 (100 mg/kg). One hour later, 3-CSAL
(50 mg/kg) was given to the experimental group. The control
animals
received

received
a saline

NSD-1015

only.

injection.

Two

One
hours

injection, the rats were sacrificed.

hour

later,

after

the

they
first

The corpus striatum,

hypothalamus, and hippocampus tissues were extracted with
75% ethanol and analyzed for their dopamine, DOPAC,

HVA,

serotonin, and 5-HIAA content by direct injection onto the
HPLC.
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7.

The effect of other carboxylated-THIQs.

Male Sprague-Dawley rats (140-165g; 42 days old) were
divided

into

three

1-carboxy-THP at

groups.

a dose of

The

first

50 mg/kg.

group
The

received

second group

received a 50 mg/kg dose of 1-CSAL. The third group received
the saline vehicle alone. One hour later the animals were
sacrificed.

Corpus striatum, hypothalamus, and hippocampus

tissues were analyzed.
5-HIAA were quantitated.

Dopamine, DOPAC, HVA, serotonin, and
Levels of 1-CSAL and 1-carboxy-THP

were determined for the respective groups of rats.

CHAPTER IV

RESULTS
A. Levels of the THIQs in the tissues analyzed.
1. 3-CSAL levels-acute studies.

a. 100 MG/KG 3-CSAL for 30 minutes.
For rats given a 100 mg/kg i.p.

dose of 3-CSAL and

sacrificed at time points of 15 and 30 minutes, the blood
levels

of 3-CSAL

and 6-a-M-3-CSAL,

and 7-a-M-3-CSAL

are

given in Table 5. The 3-CSAL blood levels were significantly
higher (p<0.01) at the 30 minute time point when compared to
the 15 minute time point. The a-methylated 3-CSAL levels
were not different between the groups at the time points
sampled.

The Bio-Rex 70 amine fraction from the blood sam-

ples were reconstituted with 250 ul of mobile phase and 100
ul were placed onto a cation-exchange column. No 6- or 7a-M-SAL content was apparent from the chromatogram (Figure
10).

Figure 11 shows the same blood sample spiked with 25

ng 7-M-SAL (60 ng/ml blood).
3-CSAL and a-methylated 3-CSALs were measured in the
striatum.

3-CSAL alone was measured in the hypothalamus
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Table 5
BLOOD LEVELS OF CARBOXYLATED THIQs AT TWO TIME POINTS FOLLOWING
100 MG/KG I.P. DOSE OF 3-CARBOXY-SAL (NG/ML + S.E.M)
295-340 g rats (approximately 72 days old)
TIME
15 MIN
30 MIN
p

3-Carboxy-Sal
553.0 + 18.7

* 1,223.5

+ 836.0

6-M-3-Carboxy-Sal

7-M-3-Carboxy-Sal

914.6 + 532.7

887.3 + 173.0

(n=2)

808.9 + 493.5

1,224.6 + 610.6

(n=4)

0.01 compared to the 15 minute 3-CSAL level

Figure 10 : Representative Chromatogram
Blood Sample of an Animal Given 100 mg/kg 3-CSAL
for 30 minutes.

Sample:

Bio-Rex 70 Amine Fraction; 100 ul of a 250 ul sample.

Column:

Partisil-SCX (10 microns)

Buffer:

12.61 g Citric Acid, 3.45 g Ammonium Phosphate Monobasic, monohydrate and
88 m1 1 N Ammonium Hydroxide per liter distilled water.

Conditions: 1 m1 per minute; 5 nA/V.
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Figure 11: Blood Sample of an Animal Given 100 mg/kg 3-CSAL
for 30 Minutes; Spiked with Salsoline.

Sample:

100 ul of a 250 ul sample of The Amine Fraction from Bio-Rex 70.

Column:

Partisil-SCX (10 micron) 250 mm x 4 mm.

Buffer:

12.61 g Citric Acid; 3.45 g Ammonium Phosphate Monobasic, monohydrate;
88 m1 Ammonium Hydroxide per liter distilled water.

Conditions:

1 m1 per minute; 5 nA/V.
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since the HPLC column lost its ability to resolve 6- and
7-M-3-CSAL after the blood and caudate samples were run on
the HPLC. This was most likely due to irreversible adsorption of tissue components.
Table 6.

The brain levels are given in

The striatal tissue contained a mean level of 2.27

ug/g 3-CSAL whereas the hypothalamic tissue contained 4.64
ug/g 3-CSAL at the 30 minute time point. The amine fractions
from the same tissue samples were chromatographed on both
cation exchange and reverse-phase columns.
Figure 12 shows the cation-exchange chromatogram of
one-fifth of the amine fraction of a caudate of an animal
given 100 mg/kg 3-CSAL for 30 minutes. No O-M-SAL was seen
in the sample.

Figure 13 shows the same brain sample spiked

with 6-M-SAL and 7-M-SAL.

Figure 14 shows the chromatogram

of one-fifth of the same caudate extract on a reverse-phase
column. No SAL was seen to be present in the sample.

When

the sample was spiked with 25 ng of SAL (625 ng/g SAL), the
SAL chromatographed separately from the peaks for dopamine
and 5-HT.

The SAL did not co-migrate with any endogenous

peaks in these tissues (Figure 15).
Table 7 shows the levels of 3-CSAL and its two mono-amethyl metabolites

in three brain regions

one hour after

3-CSAL injection in untreated rats and in rats pretreated
with peripheral or central decarboxylase inhibitors.

It is

Table 6

BRAIN LEVELS OF CARBOXYLATED THIQs AT 30 MINUTES FOLLOWING
A 100 MG/KG I.P. DOSE OF 3-CSAL

UG/G + S.E.M.
TISSUE

3-CSAL

6- and 7-M-3-CSAL

CAUDATE

2.27 + 0.3

0.39 + 0.23

HYPOTHALAMUS

4.64 + 0.4

not measured

n=4

....'.'

Figure 12; Absence of 6- or 7-M-Sal in the Striatum of a Rat
Given 100 mg/kg 3-CSAL.

Sample:

Amine Fraction from Bio-Rex 70; 100 til of a 500 ul fraction.

Column:

Rsil-Cation Exchange Resin (10 micron) 50 mm x 4mm.

Buffer:

44.14 g Citric Acid, 12.08 g Ammonium Phosphate Monobasic Monohydrate,
308 m1 1N Ammonium Hydroxide brought to a final volumn of 1 liter with
distilled water.

Conditions:

flow rate of 1 m1 per minute; 5 nA/V.
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Figure 13: Caudate Spiked with IsoSal and Salsoline (25 ng each)

Sample:

Amine Fraction from Bio-Rex 70; 100 ul of a 500 ul fraction.

Column:

Rsil-Cation Exchange (10 micron) 50 mm x 4 mm.

Buffer:

44.14 g Citric Acid, 12.08 g Ammonium Phosphate Monobasic Monohydrate,
308 m1 1 N Ammonium Hydroxide brought to a final volume of 1 liter with
distilled water.
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Figure 14:

Caudate Amine Fraction of an Animal Given 100 mg/kg
3-CSAL for 30 minutes.

Sample:

Amine Fraction from Bio-Rex 70; 100 u1 of a 500 ul fraction.

Column:

0.1 M Sodium Phosphate Monobasic Nonohydrate, 1.0 mM EDTA, pH 5.0.

Conditions:

Flow rate of 1 m1 per minute; 10 nA/V.
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Figure 15 : Bio-Rex 70 Amine Fraction from a Caudate of a Rat given
100 mg/kg 3-CSAL; Spiked with 25 ng Sal.

Sample:

100 ul of 1000 ul of the Amine Fraction from Bio-Rex 70.

Column:

BioSil- ODS 10 250 mrn x 4 mm.

Buffer:

0.1 M Sodium Phosphate Monobasic Monohydrate, 1.0 mM EDTA, pH 5.0.

Conditions: Flow rate of 1 ml per minute; 10 nA/V.
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Table 7
REGIONAL BRAIN 3-CARBOXY-SAL AND 0-METHYLATED 3-CARBOXY-SAL
ISOMERS ONE HOUR AFTER 3-CARBOXY-SAL (50 MG/KG I.P.).
UG/G + S.E.M.

BRAIN REGION

3-CSAL

6M3CSAL

7M3CSAL

CORPUS STRIATUM
CONTROL
R04-4602
NSD-1015

0.75 + 0.23
0.20 + 0.04
0.14 + 0.06

0.52+0.10
0.19 + 0.06
0.03 + 0.03

0.69 + 0.17
0.14 + 0.04
0.25 + o.os

HYPOTHALAMUS
CONTROL
R04-4602
NSD-1015

0.20 + 0.02
0.29 + 0.05
0.23 + 0.03

2.07 + 0.34
1.30 + 0.23
1.73 + 0.22

1.62 + 0.15
1. 36 + 0.11
1.74+0.11

HIPPOCAMPUS
CONTROL
R04-4602
NSD-1015

0.18 + 0.02
0.11 + 0.02
0.11 + 0.04

0.07 + 0.04
0.09 + 0.02
0.12 + 0.04

0.15 + 0.06
0.09 + 0.02
0.14 + 0.02
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apparent that there is decreased brain THIQ content when the
inhibitors R04-4602 and NSD-1015 were given.

2. Other carboxylated THIQ levels-acute experiments.
Tissue levels of 1-CSAL and 1-carboxy-THP are given in
Table 8.

The hypothalamic 1-carboxy-THP content was very

high when compared to the other to carboxylated THIQs administered.

This was possibly due to the relative lipophilic

nature of this compound when compared to the others.

3. THIQ contents between 1 and 24 hours after
a

single dose of 3-CSAL (50 mg/kg i.p.).

Large sample sizes of heart (O. 9
(1.5
if

±

±

0.1 g) and liver

0.3 g) and blood (1.5 ml) were taken to ensure that

decarboxylation products

quantitated.

The

were present,

large sample sizes,

they could

however,

be

interfered

with 3-CSAL quantitation because they resulted in corresponding

large solvent

peaks.

Therefore

despite a

good

detector sensitivity for 3-CSAL, it could not be assayed in
these tissues. The retention times for 6-methoxy-3-CSAL and
7-methoxy-3-CSAL were sufficiently removed from the larger
peaks and were therefore quantitated.

Table 8
BRAIN CARBOXYLATED THIQ LEVELS FOLLOWING A 50 MG/KG DOSE I.P.
CARBOXYLATED THIQ

UG/G + S.E.M.

1-CSAL (n=4)
CORPUS STRIATUM

o. 32 +

HYPOTHALAMUS

0.56 + 0.05

HIPPOCAMPUS

0.55 + 0.04

0.09

1-CARBOXY-THP (n=4)
CORPUS STRIATUM

0.96 + 0.29

HYPOTHALAMUS

6.48 + 1. 75

HIPPOCAMPUS

3.10 + 1.07

00
V1
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a. Rat serum 0-methylated 3-CSALs.
As seen in Table 9 and Figure 16, the highest 0-methylated 3-CSAL levels were seen at the 1 hour time point. The
rate of disappearance of the serum 0-methylated-3-CSALs was
greater between the 1 hour to 3 hours than between the 3 and
8 hours. Small amounts of 0-methylated 3-CSALs were present
at the 24 hour time point.

b. Rat liver 0-methylated metabolites.
Table 10 and Figure 17, display the time course for
levels of liver 0-methylated 3-CSALs after the single (50
mg/kg) dose of 3-CSAL. The THIQs persisted up to the 24 hour
period of time.
livers

analyzed.

6-methoxy-3-CSAL

No SAL or 7-M-SAL was seen in any of the
At the 30
content

minute time point
was

more

than

the
twice

liver
the

7-methoxy-3-CSAL content (p<0.001). The one and three hour
6-methoxy-3-CSAL

contents

were

not

significantly greater

than the 7-methoxy-isomers. The 8 and 24 hour

levels of

liver 6-methoxy-3-CSAL were significantly greater than the
7-methoxy-3-CSAL levels. Figure 18 shows a chromatogram of
6- and 7- methoxy-3-CSAL in liver tissue.

Table 9
RAT SERUM 0-METHYLATED 3-CSAL LEVELS AT VARIOUS TIMES
AFTER 3-CSAL (50 MG/KG I.P.)

TIME POINT

NG/ML + S.E.M.

6-M-3-CSAL

7-M-3-CSAL

30 MINUTES

993.20 + 264.50

1089.45 + 373.00

1 HOUR

552.75 + 155.94

662.32 + 210.62

3 HOURS

162.79 + 102.40

152.35 + 82.37

8 HOURS

38.45 +

7.18

30.50 +

10.08

24 HOURS

7.16 +

5. 14

18.35 +

13.84

n=4 per time point

Figure 16:

Rat serum a-Methylated THIQ Levels
3-CSAL Dose-Time Study.
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Table 10

RAT LIVER 0-METHYLATED 3-CSAL LEVELS AT VARIOUS TIMES
AFTER 3-CSAL (50 MG/KG I.P.)

UG/G + S.E.M.

TIME POINT

6-M-3-CSAL

7-M-3-CSAL

30 MINUTES

2.21 + 0.43

1.03+0.37

1 HOUR

1.44 + 0.64

1. 08 + 0. 76

3 HOURS

0.99 + 0.04

0.79 + 0.38

8 HOURS

0.59 + 0.68

o. 10

24 HOURS

0.19+0.13

0.04 + 0.03

n=4 per time point

+ 0.12

Figure 17:

Rat Liver THIQ Levels
3-CSAL Dose-Time Study.
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Figure 18: Chromatogram of a liver amino acid fraction from an animal
given 100 mg/kg 3-CSAL for 30 minutes.
Column: Biosil ODS-10 250mm x 4mm.
Buffer: 0.1 M Sodium phosphate monobasic, monohydrate pH 5.0.; 1.0 mM disodium EDTA.
Detector setting: 5 nA/V.
Flow rate: 1 ml/minute.
Sample: 100 ul of a 500 ul 0.02 M Sodium phosphate eluant from Bio-Rex 70.
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There was no evidence of SAL or 6- or 7-methoxy-SAL in
the rat livers despite the fact that the liver is rich in
decarboxylases.

c. Rat heart tissue a-methylated 3-CSALs.
Table 11 and Figure 19 show the levels of a-methylated
3-CSALs in heart tissue following a single dose of 3-CSAL.
The levels of the THIQs in the heart were lower than that
found in the liver.

Neither SAL nor 7-M-SAL was found to be

present in the heart tissue. The 30 min, 3, 8, and 24 hour
levels of 6- and 7-M-3-CSALs were not statistically different.

However at 1 hour there was 73% more 6-M-3-CSAL than

7-M-3-CSAL (p<0.01).

d. Striatal levels of 3-CSAL and its two
a-methylated metabolites after
3-CSAL (50 mg/ kg i.p.).
The presence of striatal 3-CSALs was documented in
Table 12 and Figure 20. The levels were highest at the 1
hour time point. Based upon the levels at the three hour and
eight hour time points, the half-life of 3-CSAL was approximately 120 minutes.

Also, there was no evidence of reduc-

tive decarboxylation products in this tissue.

Table 11
RAT HEART LEVELS OF 0-METHYL-3-CSAL ISOMERS AT VARIOUS TIMES
FOLLOWING 3-CSAL (50 MG/KG I.P.)

NG/G + S.E.M.

TIME POINT

6-M-3-CSAL

7-M-3-CSAL

30 MINUTES

32.63 + 15.99

27.95 + 12.76

1 HOUR

49.07 + 18.60

28.44 +

7.35

3 HOURS

9.67 + 0.26

10.01 +

0.90

11.50 +

0.65

8 HOURS

13.01 +

0. 74

24 HOURS

0.00 +

0.00

n=4 per time point

0.00 + 0.00

Figure'I9:

Rat Heart 0-Methylated THIQ Levels
3-CSAL Dose-Time Study.
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Table 12
STRIATAL 3-CSAL AND 0-METHYL ISOMERS AT VARIOUS TIMES
FOLLOWING 3-CSAL (50 MG/KG I.P.)

UG/G + S.E.M.

TIME POINT

3-CSAL

30 MINUTES

0.69 + 0.21

1. 13 +

o. 36

0.96 + 0.31

1 HOUR

0.76 + 0.08

1.15 + 0.09

0.81 + 0.08

3 HOURS

0.33 + 0.18

0.38 + 0.22

0.00 + 0.00

8 HOURS

0.00 + 0.00

0.00 + 0.00

0.00 + 0.00

24 HOURS

0.00 + 0.00

0.00 + 0.00

0.00 + 0.00

6-M-3-CSAL

n=4 per time point

..

:'.'

7-M-3-CSAL

Figure 20:

Striatal THIQ levels After i.p. 3-CSAL.
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B. The effects of carboxylated THIQs
on 5-HT and 5-HIAA.
1. 3-CSAL acute experiments-fluorescent studies.
a. The effect of 3-CSAL on striatal
5-HT levels.
The three i.p.
400 mg/kg.

doses investigated were 50,

150, and

As seen in Table 13, striatal serotonin was sig-

nificantly increased for all three doses as compared to the
control values (+70%; +71%; +90%).

Hypothalamic serotonin

levels were somewhat depressed but the changes were not significant at the p<0.05 level.

b. One-hour pretreatment with the peripheral
dopa-decarboxylase inhibitor,
Benserazide (R04-4602).
When

3-CSAL

was

given

to

rats

pretreated

with

R04-4602, striatal serotonin was elevated 336% when compared
to the control levels but 5-HIAA levels were not different
from

the controls.

There was

no significant

difference

between experimental and control hypothalamic serotonin or
5-HIAA.

The hippocampus showed no difference in serotonin

or 5-HIAA content levels. See Table 14.

Table 13
THE EFFECT OF ACUTE 3-CSAL (50 MG/KG I.P.) ON
SEROTONIN LEVELS IN RAT STRIATUM AND HYPOTHALAMUS UG/G + S.E.M.
STRIATUM

3-CSAL DOSE
CONTROL

0.52 + 0.08

50 MG/KG

0.89 + 0.16

150 MG/KG

0.90 + 0.14

400 MG/KG

0.99 + 0.11

*

HYPOTHALAMUS
1.53 + 0.15

*
*
*

1.05 + 0.07
1. 29 + 0.14
1.41 + 0.19

denotes p < 0. 01 compared to controls.

Rats 210-270g; 60 days old.
Measured by Fluorescence.
n=6 per group

......
w

0

Table 14
THE EFFECT OF 3-CSAL AND R04-4602 ON REGIONAL BRAIN SEROTONIN AND 5-HIAA
UG/G
TISSUE

± S.E.M.
5-HT

5-HIAA

CORPUS STRIATUM

*

0.91 + 0.06

EXPERIMENTAL

4.38 + 0.95

CONTROL

1.30 + 0.43

0.88 + 0.11

EXPERIMENTAL

o. 39 +

0.08

0.99 + 0.21

CONTROL

0.45 + 0.22

0. 78 + 0.10

EXPERIMENTAL

0.34 + 0.01

0.55 + 0.03

CONTROL

0. 38 + 0.01

0.53 + 0.03

HYPOTHALAMUS

HIPPOCAMPUS

* denotes
Rats 300-400g; 100 days old.
Measured by Fluorescence.

p< 0.01 compared to controls.
n=4 per group
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c. One-hour pretreatment with a total
(central and peripheral)
dopa decarboxylase inhibitor: NSD-1015.
Rats pretreated with sufficient NSD-1015 to totally
inhibit decarboxylation had significantly elevated striatal
serotonin levels one hour after 3-CSAL when compared to rats
which were given the inhibitor followed by saline.

Striatal

5-HIAA was significantly depleted when compared to the control group.
Hypothalamic serotonin was significantly elevated but
5-HIAA was not significantly changed when compared to controls For the hippocampus, there was no significant difference between the serotonin or 5-HIAA for the experimental
and the control groups (Table 15).

Table 15
THE EFFECT OF 3-CSAL AND NSD-1015 ON REGIONAL
BRAIN LEVELS OF 5-HT AND 5-HIAA (UG/G + S.E.M.).
TISSUE

5-HT

5-HIAA

CORPUS STRIATUM
EXPERIMENTAL

5.96 + 0.59

CONTROL

2.29 + 0.21

**

0.54 + 0.05
0.83 + 0.07

HYPOTHALAMUS
0.58 + 0.05

. EXPERIMENTAL

*

1.04 + 0.11

0.41 + 0.04

1.06 + 0.06

EXPERIMENTAL

0.39 + 0.02

0.29 + 0.02

CONTROL

0.43 + 0.06

0.31 + 0.07

CONTROL
HIPPOCAMPUS

** denotes
* denotes
Rats 300-400g; 100 days old.
Measured by Fluorescence.

p <0.01 compared to controls.
p <0.05 compared to controls.
n=4 per group

*
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d. The effect of chronic 3-CSAL (5 days)
on regional brain 5-HT and 5-HIAA levels.
Following the chronic administration of 3-CSAL, striatal serotonin was significantly depleted to 48% of control.
The serotonin precursor amino acid, tryptophan was significantly elevated by 21% over the control value.

5-HIAA was

not significantly different between groups.
In the

hypothalamic tissue,

serotonin was

signifi-

cantly depleted to 82% of the control but there was no significant difference in tryptophan content between groups The
hypothalamic 5-HIAA levels were significantly reduced in the
experimental group by 24%.

See Table 16.

Table 16
RAT STRIATAL 5-HT AND 5-HIAA AT VARIOUS TIMES
AFTER 3-CSAL (50 MG/KG I.P.)
TIME POINT

UG/G + S.E.M.

5-HT

5-HIAA

CONTROL

0.44 + 0.04

0.52 + 0.04

30 MINUTES

o. 66 +

0.54 + 0.07

1 HOUR

1.01 + 0.30 *

0.76 + 0.07 *

3 HOURS

1. 32 + 0. 51 *

0.43 + 0.06

8 HOURS

2.08 + 0.60 *

0. 72 + 0.09 *

24 HOURS

0.53 + 0.03 *

0.97 + 0.08 **

0.11 *

**denotes pc:::O.Ol compared to controls.
* denotes p < 0. 05 compared to controls.
n=4 per time point

..-

0
00
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2. HPLC determinations.

a. The time course effect of a single
dose 50 mg/kg i.p.

of 3-CSAL

on 5-HT and 5-HIAA.

The effects of a single 50 mg/kg dose of 3-CSAL was followed
at the time points of 30 min., 1, 3, 8, and 24 hours. Striatal serotonin was significantly elevated up to 8 hours afer
3-CSAL was given. At 24 hours, serotonin approached control
values but it was still significantly higher (20% over control).
Striatal 5-HIAA was elevated slightly at 30 min. The
change however was not statistically significant. At the one
hour time point there was
striatal 5-HIAA.

a significant increase in the

The three hour time point showed a non-

significant decrease in the 5-HIAA levels when compared to
controls.

At

24

hours

there

was

again

a

significant

increase in the 5-HIAA levels of the experimental group when
compared to the controls.

See Table 17 and Figure 21.

Table 17
THE EFFECT OF CHRONIC 3-CSAL ON TRYPTOPHAN, SEROTONIN, AND
5-HIAA IN RAT STRIATUM AND HYPOTHALAMUS UG/G + S.E.M.
COMPOUND

STRIATUM

HYPOTHALAMUS

TRYPTOPHAN
CONTROL

3.27 + 0.08

5.06 + 0.79

EXPERIMENTAL

3.96 + 0.17

3.88 + 0.36

SEROTONIN

*

0.37 + 0.01

CONTROL

0.33 + 0.01

EXPERIMENTAL

().16 + 0.02

0.30 + 0.01

CONTROL

0.40 + 0.05

0.77 + 0.04

EXPERIMENTAL

0.45 + 0.06

0.59 + 0.01

5-HIAA

* denotes
Rats 112-152g; 40 days old.

p <0.01 compared to controls.
n= 12 per group

......

......

Measured by Fluorescence.

0

Figure 21:

Striatal Serotonergic Changes
3-CSAL Dose-Time Study.
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b. The effect of 3-CSAL on 5-HT synthesis.
If 3-CSAL increased the turnover of 5-HT, then a total
inhibition of aromatic amino acid decarboxylase by R04-4602
would lead to an increased accumulation of 5-HTP. Table 18
demonstrates that 3-CSAL does not increase the synthesis of
5-HT in decarboxylase inhibited rats.

c. The age-dependent increase of
striatal 5-HT by 3-CSAL.
As can be seen in Tables 19 and 20, 3-CSAL did not
have a significant effect upon striatal or hypothalamic 5-HT
content 8 hours after it was given to the older rats.

In

fact the only significant difference between the groups was
that the HVA content was

significantly different between

groups. When the younger rats were given 3-CSAL, striatal
5-HT levels were significantly elevated at 4 hours after the
dose was given.

Striatal 5-HT was further elevated at the 8

hour time point (p<O.Ol)

(Table 21).

Striatal DA

levels

were not affected at either of the time points investigated.
The hypothalamus showed no significant difference in either
DA or 5-HT content.

Table 18
STRIATAL 5-HYDROXYTRYPTOPHAN LEVELS FOLLOWING TOTAL AROMATIC AMINO ACID
DECARBOXYLATION INHIBITION BY 800 MG/KG R04-4602 FOLLOWED BY 3-CSAL

GROUP

5-HYDROXYTRYPTOPHAN

(UG/G

±

S.E.M.).

CONTROL

18.00 + 4.12

n=5

EXPERIMENTAL

22.71 + 3.42

n=7

Rats 214-407g; 6-10 months of age.
Measured by HPLC.

.~

':

Table 19
THE EFFECTS OF 3-CSAL 50 MG/KG I.P. FOR EIGHT HOURS UPON THE
CORPUS STRIATUM OF 10 MO OLD RATS

UG/G . + S .E.M.
EXPERIMENTAL GROUP

COMPOUND

CONTROL GROUP

DOPAMINE

6.47 + 1.52

6.67 + 2.07

DOPAC

3.41 + 0.82

1.82 + 0. 60

5-HT

0.44 + 0.13

0.34 + 0.08

5-HIAA

0.31 + 0.22

0.43+0.16

HVA

1.24 + 0.15

0.57 + 0.28 *

n=4 per group
*denotes pc:::0.01 as compared to controls.
Rats 392-455g; 10-12 months of age.
Measured by HPLC.

Table 20
THE EFFECTS OF 3-CSAL 50 MG/KG I.P. FOR EIGHT HOURS
UPON THE HYPOTHALAMUS OF OLDER RATS
UG/G + S.E.M.
COMPOUND

CONTROL GROUP

DOPAMINE

0.28 + 0.08

0.38 + 0.14

DOPAC

0.18 + 0.04

0.17 + 0.04

5-HT

1.69 + 0.39

1. 66 + 0.28

5-HIAA

0.63 + 0.14

0.69 + 0.15

HVA

0.19 + 0.03

0.36 + 0.05

n=4 per group
Rats 392-455g; 10-12 months of age.
Measured by HPLC.

EXPERIMENTAL GROUP

Table 21
THE EFFECTS OF 3-CSAL 50 MG/KG I.P. FOR EIGHT HOURS
UPON THE CORPUS STRIATUM OF YOUNGER RATS

UG/G + S.E.M.

GROUP

DOPAMINE

4 Hour Saline

5.54 + 0.65

0.63 + 0.14

4 Hour 3-CSAL

4.99 + 0.43

1.00 + 0.09

8 Hour Saline

4.90 + 0.54

0.78 + 0.13

8 Hour 3-CSAL

4.97 + 0.38

1.21 + 0.05

Combined Controls

5.22 + 0.39

0.69 + 0.08

*

n=4

*

n=5

n=4

*

n•5

denotes p< 0.01 as compared to the time matched controls.

Rats 94-105g; 35 days of age.
Measured by HPLC.

5-HT
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d. The effect of other carboxylated THIQs
on 5-HT and 5-HIAA.
1. One hour after 1-CSAL (50 mg/kg i.p.).
The

dopamine-pyruvic

acid

condensation

product,

1-CSAL, had a significant effect upon the striatal serotonergic system, resulting in significantly elevated 5-HT levels.

5-HIAA also was significantly elevated in this tissue.
1-CSAL had no effect on the hypothalamic serotonin

content.

However a 5-fold elevation of 5-HIAA was seen in

this tissue.
Neither hippocampal 5-HT nor 5-HIAA was affected by
the dose of 1-CSAL (Table 22).

2. One hour after 1-carboxy-THP
(50 mg/kg i.p.).
1-carboxy-THP,

the condensation product of dopamine

and 3,4-dihydroxyphenylpyruvic acid, significantly increased
both 5-HT and 5-HIAA content in the corpus striatum.
Both hypothalamic and hippocampal 5-HT and 5-HIAA contents were unaffected by this acute dose of 1-carboxy-THP.
See Table 23.

Table 22
REGIONAL BRAIN 5-HT AND 5-HIAA LEVELS ONE HOUR FOLLOWING
ACUTE 1-CSAL TREATMENT (50 MG/KG I.P.)
TISSUE

UG/G + S.E.M.
5-HIAA

5-HT

CORPUS STRIATUM

*

1.32 + 0.15

EXPERIMENTAL

1.26 + 0.16

CONTROL

0.51 + 0.02

o. 72 +

EXPERIMENTAL

1.06 + 0.10

1.56 + 0.10

CONTROL

0.96 + 0.04

0.30 + 0.02

EXPERIMENTAL

0.18 + 0.02

0.20 + 0.02

CONTROL

0.23 + 0.02

0.23 + 0.02

*

0.07

HYPOTHALAMUS

HIPPOCAMPUS

**

denotes

~

0.01;

*

denotes p <0.05 as compared to controls

n==4 per group
Rats 140-165g; 42 days of age.
Measured by HPLC.

**

Table 23
REGIONAL BRAIN 5-HT AND 5-HIAA LEVELS ONE HOUR FOLLOWING
ACUTE 1-CARBOXY-THP TREATMENT (50 MG/KG I.P.)
TISSUE

5-HT

UG/G + S.E.M.
5-HIAA

CORPUS STRIATUM
'EXPERIMENTAL

1.42 + 0.18

CONTROL

*

1.69 + 0.14

0.51 + 0.02

0. 72 + 0.07

EXPERIMENTAL

0.90+0.10

0.24 + 0.04

CONTROL

0.96 + 0.04

0.30

EXPERIMENTAL

0.27 + 0.05

0.26 + 0.05

CONTROL

0.23

± 0.02

0.23 + 0.02

*

HYPOTHALAMUS

± 0.02

HIPPOCAMPUS

* denotes

p c::O.OS as compared to controls.

Rats 140-165g; 42 days of age.
Measured by HPLC.

n•4 per group

N

0
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C. The effects of carboxylated THIQs on the levels of
catecholamines and their acid metabolites.
1.

Acute fluorometric determinations.
a. Striatal and hypothalamic catecholamine content one hour after 3-CSAL.

One hour after the 50 mg/kg i.p.

3-CSAL dose, there

was a non-significant decrease of striatal and hypothalamic
dopamine.

Hypothalamic norepinephrine levels were not sta-

tistically different between groups (see Table 24).
b. Striatal and hypothalamic content
one hour after 3-CSAL (50 mg/kg i.p.)
in Benserazide (R04-4602) treated rats.
When preceded by a peripheral decarboxylase inhibitor,
the 50 mg/kg dose of 3-CSAL lowered striatal dopamine to
52.3% of the level of the control group (Table 25).

Hypoth-

alamic dopamine was also significantly reduced, but not to
the same degree.

Hypothalamic norepinephrine content was

not altered.
c. Striatal and hypothalamic content
one hour after 3-CSAL (50 mg/kg i.p.)
in NSD-1015 pretreated rats.

Table 24
REGIONAL CATECHOLAMINE LEVELS ON HOUR FOLLOWING ACUTE
3-CSAL TREATMENT (50 MG/KG I.P.) UG/G + S.E.M.
TISSUE

LEVELS

CORPUS STRIATUM
CONTROL DA

7.88 + 0.76

EXPERIMENTAL DA

6.73 + 1.45

HYPOTHALAMUS
·CONTROL DA

2.11 + 0.25

EXPERIMENTAL DA

1.97 + 0.98

CONTROL NE

2.38 + 0.21

EXPERIMENTAL NE

2.52.+ 0.59

Rats 300-400g; 100 days old.

n=5 per group

Measured by Fluorescence.
.......
N
N

Table 25
REGIONAL CATECHOLAMINE LEVELS ONE HOUR FOLLOWING R04-4602
AND ACUTE 3-CSAL TREATMENT (50 MG/KG I.P.) UG/G

±

S.E.M.

LEVELS

TISSUE
CORPUS STRIATUM
EXPERIMENTAL DA

4.31 + 0.44

CONTROL DA

8.24 + 0.50

**

HYPOTHALAMUS
EXPERIMENTAL DA

2.12 + 0.12

CONTROL DA

2.86 + 0.09

EXPERIMENTAL NE

1. 98

CONTROL NE

2.62 + 0.13

**

denotes P< 0.01;

*

Rats 300-400g; 100 days of age.
Measured by Fluorescence.

*

+ 0.19

denotes p<O.OS as compared to controls
n=6 per group
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In the presence of a total dopa decarboxylase inhibitor, 3-CSAL significantly reduced striatal dopamine levels
when compared to rats given the inhibitor alone. Hypo- thalamic

dopamine

levels

were

not

significantly

Hypothalamic norepinephrine content was not

affected.

significantly

affected (Table 26).

d. Striatal dopamine levels one hour
following increasing doses of 3-CSAL
(50, 150, or 400 mg/kg i.p.).
The effect of the 3-CSAL at the doses of 50, 150, or
400 mg/kg was investigated. As seen in Table 27, there was
no significant effect upon striatal dopamine levels by any
of the doses given.

2. HPLC determinations.

a. The effect of chronic 3-CSAL
(50 mg/kg i.p., three times
daily for 5 days) on catecholamines.
One hour following the final dose of 3-CSAL, the striatal and hypothalamic dopamine of the experimental group

Table 26
REGIONAL CATECHOLAMINE LEVELS FOLLOWING TREATMENT WITH A TOTAL
DECARBOXYLASE INHIBITOR FOLLOWED BY ACUTE 3-CSAL (50 MG/KG I.P.)
FOR ONE HOUR.

UG/G + S.E.M.
LEVELS

TISSUE
CORPUS STRIATUM
CONTROL DA

7.32 + 0.47

EXPERIMENTAL DA

4. 74 +

**

o. 71

HYPOTHALAMUS
CONTROL DA

1.97 + 0.04

EXPERIMENTAL DA

2.05 + 0.29

CONTROL NE

2.29 + 0.24

EXPERIMENTAL NE

1.89 + 0.21

**

denotes P< 0.01 as compared to controls.

Rats 300-400g; 100 days of age.
Measured by Fluorescence.

n=6 per group

Table 27
THE EFFECT OF ACUTE 3-CSAL (50 MG/KG I.P.) ON DOPAMINE
LEVELS IN THE CORPUS STRIATUM
DOSE OF 3-CSAL

UG/G + S.E.M.
LEVELS

CONTROL

7.32 + 0.47

50 MG/KG

7.29 + 0.88

150 MG/KG

6. 35

400 MG/KG

6.65 + 0.56

+

0. 53

Rats 210-270g; 60 days of age.
Measured by Fluorescence.
n•6 per group
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were essentially the same as

that of the control group.

Hypothalamic norepinephrine levels were unchanged (See Table
28).

b. Acute 3-CSAL studies-catecholamine
and metabolite studies.

1.

Striatal levels of DA, DOPAC, and HVA
between 30 minutes and 24 hours after
3-CSAL (SO mg/kg i.p.).

The effect of a single SO mg/kg dose of 3-CSAL was
followed at the time points of 30 min.,

1, 3, 8, and 24

hours. The levels of striatal dopamine, DOPAC, and HVA are
listed in Table 29. There was no statistical difference in
striatal dopamine levels at any of the times compared to the
control group.
Thirty minutes post dosage, there was no significant
difference

in DOPAC

levels

as

compared to the controls.

Non-statistical increases in DOPAC levels were seen at one
and three hours. Eight hours after the dose of 3-CSAL, striatal DOPAC was elevated greater than two-fold as compared to
the controls The twenty-four hour DOPAC
significantly elevated.

levels were also

The DOPAC elevation was greater at

twenty-four hours than at eight hours.

Table 28
THE EFFECT OF CHRONIC 3-CSAL ON DOPAMINE AND NOREPINEPHRINE
IN RAT STRIATUM AND HYPOTHALAMUS

DOPAMINE

STRIATUM

UG/G + S.E.M.

HYPOTHALAMUS

CONTROL

8.43 +

o. 73

2.86 +·0.46

EXPERIMENTAL

8. 38 + 1.24

2.87 + 0.40

NOREPINEPHRINE
CONTROL

2.22 + 0.16

EXPERIMENTAL

2.24 + 0.31

The 3-CSAL was given every 8 hours for 5 days. Animals
were sacrificed 1 hour after the last dose.
Rats 112-152g; 40 days of age.

....

N

Measured by Fluorescence.

n•12 per group

00

Table 29
DA, HVA, AND DOPAC LEVELS IN THE CORPUS STRIATUM AT VARIOUS
TIMES AFTER ACUTE 3-CSAL (50 MG/KG I.P.)

TIME POINT

UG/G + S.E.M.

DOPAMINE

DOPAC

HVA

CONTROL

7.13 + 0.88

2.13 + 0.09

1.13 + 0.06

30 MINUTES

7. 87 + 1.24

2.03 + 0.07

0.48 + 0.19

1 HOUR

7.78 + 0.61

3.08 + 1.02

0.98 + 0.44

3 HOURS

7.09 + 1. 95

2.82 + 0.83

1.05 + 0.07

8 HOURS

9.15 + 2.32

4.50 + 0.32

24 HOURS

8. 75 + 1.17

5.19 + 0.42

**

denotes p < 0.01;

* denotes

Rats 250-350g; 90 days of age.
Measured by HPLC.

n=4 per group

**
**

1. 35 + 0.06
1.69 + 0.51

p <0.05 as compared to controls.

**

*
*
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The

HVA

levels

at

the

thirty minute time point as compared to the controls.

At

one and three hours,

were

significantly

the HVA

lowered

levels of the experimental

groups were statistically the same as that for the control
group. At eight hours the HVA levels for the experimental
group was significantly elevated over that for the control
group. The HVA levels were further elevated at twenty fourhours.

See Figure 22.

2. Levels of DA, DOPAC, and HVA in striatum
and hypothalamus following 3-CSAL
(50 mg/kg i.p.)

in Benserazide (R04-4602)

pretreated rats.
Striatal dopamine was significantly depleted in the
experimental group.

Striatal DOPAC levels were also signif-

icantly depleted, but HVA levels remained unchanged.
While the peripheral dopa decarboxylase inhibitor plus
3-CSAL had effects upon the dopaminergic system in the corpus

striatum,

no effects were

seen in the hypothalamus:

there was no significant effect on dopamine levels; HVA levels were non-significantly lowered (Table 30).

3. Animals given a total decarboxylase
inhibitor followed by 3-CSAL.

Figure 22:

Striatal Dopaminergic Changes
3-CSAL Dose-Time Study.
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Table 30

THE EFFECT OF 3-CSAL AND R04-4602 ON REGIONAL DOPAMINE,
UG/G + S.E.M.

DOPAC, AND HVA LEVELS

TISSUE

DOPAMINE

DOPAC

HVA

CORPUS STRIATUM
EXPERIMENTAL

3.68 + 0.12
,

CONTROL

**

0.66 + 0.06

*

0.48 + 0.06

7.04 + 0.33

1.09 + 0.11

0.48 + 0.07

1.60 + 0.10

0.20 + 0.03

0.18 + 0.05

0.15 + 0.02

0.24 + 0.06

HYPOTHALAMUS
EXPERIMENTAL

i

1.73 + 0.18

CONTROL

**

denotes p<!0.01;

Rats 196-205g; 50 days of age.
· Measured by HPLC.

n•4 per group

* denotes

P< 0.05 as compared to controls.
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Total dopa decarboxylase inhibition followed by 3-CSAL
resulted in a significant depletion of dopamine levels in
the

corpus

striatum.

DOPAC

levels

for

the

experimental

group were significantly reduced when compared to controls.
Also, HVA levels were significantly less for the experimental group when compared to the controls.
The

experimental

treatment

produced

no

significant

difference in hypothalamic dopamine levels when compared to
the controls; DOPAC levels were significantly elevated and
there was a large non-significant increase in HVA levels.
See Table 31.

4. The effect of 1-CSAL (50 mg/kg i.p.)
on catecholamine and acid levels.
A 50 mg/kg i. p.

dose of 1-CSAL had no effect upon

striatal dopamine or DOPAC levels after one hour.
significant

effect

(p<0.01)

of 1-CSAL upon the

However a
striatal

dopaminergic system is indicated by the increased HVA levels.
The hypothalamic dopaminergic system was more extensively affected by 1-CSAL.

Hypothalamic dopamine and DOPAC

were significantly elevated when compared to controls.
trary to the striatum,
altered by acute 1-CSAL.

hypothalamic
See Table 32.

HVA

Con-

levels were not

Table 31
TISSUE DOPAMINE AND ACID METABOLITES LEVELS FOLLOWING
TOTAL DECARBOXYLASE INHIBITION AND 3-CSAL (50 MG/KG I.P.).
UG/G + S.E.M.
DOPAMINE

TISSUE

HVA

DOPAC

CORPUS STRIATUM

*.

EXPERIMENTAL

5. 90 + 0. 53.

CONTROL

7.62 + 0.43

0.36 + 0.02

EXPERIMENTAL

1.68 + 0.34

0.22 + 0.02

CONTROL

1. 66 + 0.16

0.16 + 0.01

0.24 + 0.03

**

0.31 + 0.10

*

0.53 + 0.04

HYPOTHALAMUS

**

denotes p< 0.01;

Rats 200-214g; 52 days of age.
Measured by HPLC.

* denotes

*

2.80 + 0.27
1.67 + 0.75

p< 0.05 as compared to controls.

n•4 per group

....

IJ,)

VI

Table 32
TISSUE DOPAMINE AND ACID METABOLITES FOLLOWING 1-CSAL
UG/G

± S.E.M.

DOPAMINE

TISSUE

DOPAC

HVA

CORPUS STRIATUM
EXPERIMENTAL

7.81 + 1.06

1. 85 + 0.24

0.89 + 0.07

CONTROL

7.65 + 0.74

1.78 + 0.10

0.43 + 0.10

*

HYPOTHALAMUS
EXPERIMENTAL

2.66 + 0.09

CONTROL

2.08 + 0.23

**

denotes p < 0.01;

Rats 140-165g; 42 days of age.
Measured by HPLC.

*

0.56 + 0.14
0.34 + 0.08

* denotes

**

0.28 + 0.04
0.30 + 0.02

p < 0.05 as compared to controls.

n•4 per group
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5. The effect of 1-carboxy-THP (50 mg/kg i.p.)
on the catecholamine and acid
metabolite levels.
A 50 mg/kg i.p. dose of 1-carboxy-THP had no effect
upon the striatal dopamine or DOPAC levels after one hour.
However striatal HVA levels were significantly elevated by
acute 1-carboxy-THP treatment.

Hypothalamic DA, DOPAC, and

HVA levels for the experimental group was not statistically
different from controls (Table 33).

Table 33
TISSUE DOPAMINE AND ACID METABOLITES FOLLOWING ACUTE
1-CARBOXY-THP (50 MG/KG I.P.)

TISSUE

DOPAMINE

UG/G

± S.E.M.
DOPAC

HVA

CORPUS STRIATUM
EXPERIMENTAL

8.18 + 0.76

1. 98

+ 0.05

0.93 + 0.13

CONTROL

7.65 + 0.75

1. 78 + 0.10

0.43 + 0.01

EXPERIMENTAL

2.21 + 0.21

0.48 + 0.10

0.24 + 0.04

CONTROL

2.08 + 0.23

0.34 + 0.08

o. 30 +

*

HYPOTHALAMUS

* denotes

p< 0.05 as compared to controls.

0.02

w

Rats 140-165g; 42 days of age.
Measured by HPLC.

00

n•4 per group

CHAPTER V
DISCUSSION

A. Lack of evidence for in vivo decarboxylation
of 3-CSAL to SAL or a-methyl-SALs.
Animals given a 100 mg/kg dose of 3-CSAL had relatively greater THIQ levels at 30 minutes than at the 15 minute time point. Non-oxidative decarboxylation of 3-CSAL or
of

its

a-methyl

metabolites

could

have

produced

SAL,

6-M-SAL, or 7-M-SAL. Despite the fact that large (ug/g) levels of 3-CSAL were present in the blood and brain, neither
SAL, 7-M-SAL, nor 6-M-SAL was seen. Based on the electrochemical responses
ity),

(and corresponding limits of sensitiv-

SAL had to constitute <0. 05% of the 3-CSAL

(10 .17

nMoles/g) found in the striatum, or <0.02% of the injected
THIQ (20.77 nMoles/g) present in the hypothalamus if it were
to

be

present

nMoles/ml 3-CSAL.

at

analysis.

The

blood

contained

5.48

Neither SAL nor a-methylated SALs were

seen in the blood. Based upon the 5. 48 nMole/ml level of
3-CSAL, <0.09% of the 3-CSAL was decarboxylated peripherally
in animals given a 100 mg/kg i.p.

dose of 3-CSAL for 30

minutes. SAL was not apparent in heart or liver tissues analyzed even though these tissues are rich in decarboxylases.
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Collins and Weiner (30) previously noted that 3-CSAL
was not an inhibitor of DDC in vitro further indicating that
3-CSAL is a poor substrate for this enzyme in rats. Relatively high levels of 6-M-3-CSAL and 7-M-3-CSAL were seen in
the brain tissue but no 6-M-SAL or 7-M-SAL were detected
there above the limits of sensitivity described above.

It

is probable then that the 0-methylated-3-CSALs are also poor
substrates

for

decarboxylases.

Simi liar to

the 3-CSALs,

alpha-methyl-para-tyrosine is not decarboxylated in vivo.
In contrast, 1-dopa analogues such as alpha-MD and AMMT are
readily

decarboxylated

(40,41,42,43).
enzyme which

non-oxidatively

in

vivo

Also 3-CSAL was not decarboxylated by the
decarboxylates pipecolic acid

to piperidine

(44,45).
THIQs
tively

carboxylated at the 1-position can be oxida-

decarboxylated

in

vitro

to

their

corresponding

3,4-dihydroisoquinolines by anodic oxidation at low electrochemical potentials

(82),

aqueous media (83),

and by the plant enzymes laccase and

peroxidase

(84).

prolonged treatment

Origitano

found

<57

in neutral

pMoles

of

1,2-dihydro-SAL but large amounts of 1-CSAL present in the
brains of rats chronically treated with 1-CSAL (91). Rapid
a-methylation

and

conjugation of

the

carboxylated THIQs

might be expected to block the oxidative decarboxylation.
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B. Is it possible that 3-CSAL is metabolized
beyond a-methylation?
a-methylation and decarboxylation were the two major
routes of metabolism of the carboxylated THIQs which were
addressed in this dissertation. It is possible that other
routes of metabolism exist for the carboxylated THIQs.
metoquinol

is

activity(85).

Tri-

a catechol THIQ with known bronchodilation
Only 11.5% of trimetaquinol is excreted as

the free drug; 27.5% is excreted as a-methylated trimetaquinol; and 61% is excreted as the glucuronide conjugate. Sulfate conjugation of biogenic amines and their metabolites is
also an important pathway of metabolism in brain.
N-oxidation is another metabolic alternative. Various
drugs such as pentobarbital and ethanol are known to induce
hepatic microsomal oxidative systems. Dajani and Saheb (16)
found that varying metabolic conditions could favor oxidation of beta-carbolines both in vitro and in vivo.
products were N-oxides.

It

The

is possible therefore that

an

alternate pathway of THIQ metabolism could be the formation
of N-oxides and fully aromatic compounds. Hamilton and Gause
(86) have suggested the formation of N-oxides from SAL and
DesmethylSAL after incubation in mild alkaline conditions.

C. Lack of in vivo stereospecificity for a-methylation
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of 3-CSAL by COMT.
Endogenous catecholamines have been shown to be stereospecific substrates for COMT.

Catecholic THIQs have been

shown to be inhibitors of COMT in vitro (87) and in vivo and
themselves are a-methylated (88,89,90).

Studies with puri-

fied rat liver COMT have monitored the stereospecific O-rnethylation of DesmethylSAL and its N-methyl analog (89), and
THP (32).

Consistently, the compounds were predominantly

a-methylated at the 7-position. Bail et al (89) found that
SAL and NorSAL, given centrally to rats, were predominantly
a-methylated at the 7-position. Origitano et al (91) found
that SAL and 1-CSAL (both DA derived catecholic THIQs) were
stereo-specifically a-methylated at the 7- (para) position.
This is in contrast to DA which is specifically a-methylated
meta-to the side chain.
L-dopa, the parent amine of 3-CSAL is stereospecifically a-methylated at the hydroxyl group meta- to the side
chain

in vivo

a-methylated.

(87).

3-CSAL

Equal amounts

is however
of 6-M-

non-specifically

and 7-M-3-CSAL were

found in the serum of animals given a dose of 3-CSAL. Origitano deduced that a hydrophobic region may be present in the
active site of COMT which prevents random binding of substrates

(91).

Charged groups on substrate molecules are

directed away from the hydrophobic centers giving a stereos-
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pecific orientation.

The presence

of the carboxylic acid

moiety at the 3-position in 3-CSAL provides an equal opportunity for a-methylation at either the hydroxyl group metaor

para- to the side chain.

D. The levels of 6-M-3-CSAL were consistently
higher than 7-M-3-CSAL in tissue samples.

The levels of the two a-methylated isomers of 3-CSAL
were essentially the same

in the

When a single dose of 3-CSAL was

serum samples

analyzed.

followed over a

24 hour

period of time, there was no difference in content of the
two isomers at the 30 minute time point. However, significantly

more

6-M-3-CSAL

was

present

in

the

brain

than

7-M-3-CSAL at both the 1 and 3 hour time points (p<0.01). At
the 30 minute time point the liver 6-M-3-CSAL content was
more than twice the 7-M-3-CSAL content

(p<O. 001).

The one

hour 6-M-3-CSAL content was non-significantly greater than
the

7-M-3-CSAL

content.

6-M-3-CSAL levels
7-M-isomer.

At

the

3

hour

were non-statistically

time

point

the

greater than

the

The 8 and 24 hour liver levels of 6-M-isomer

were significantly greater than

the 7-M-isomer.

In heart

tissue, the 30 minute, 3, 8, and 24 hour levels of the two
isomers were not statistically different. However at 1 hour,
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there was 73% more 6-M-3-CSAL than 7-M-3-CSAL (p<O.Ol).
hour

after

a 50

i. p.

mg/kg

dose of

One

3-CSAL hypothalamic

6-M-3-CSAL was 24% greater than the 7-M-3-CSAL content.
There are several possibilities for these results. One
is

that

the

7-M-isomer.

6-M-isomer
A second

is

formed

more

explanation

could

easily
be

than

the

significantly

better storage of 6-M-3-CSAL than the 7-isomer in nerve terminals. A related third explanation is that either conjugation,

N-oxidation

and/or

exodus

of

the

7-isomer

is

much

faster in these tissues.

E. The effects of the THIQs: neurotransmitter content
and turnover in the tissues analyzed.

The

presence

of

the

THIQs

in

the

different

brain

regions, and the neurochemical effects seen must be viewed
in

light

of

the

type

of

innervation

that

the

tissue

receives, and the relative turnover of the respective biogenic

amine

neurotransmitters.

Smith

et

al.

(92)

ranked

seven brain regions with respect to neurotransmitter content
and turnover. The seven brain regions examined were the cerebral cortex,
mus),

diencephalon

hippocampus,

(which

mesencephalon,

contains the

hypothala-

pons-medulla,

striatum,

and telencephalon. A summary of their work is provided in
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Table 34. With a rank of 1 being highest and 7 being lowest,
we can use the ranking system of Smith et al.

to rate the

tissues analyzed in this dissertation.
The striatum has the highest DA content and the fastest DA turnover; although the striatum ranked sixth in 5-HT
content, the turnover of 5-HT was ranked second. The hypothalamus

ranked fourth in both

DA content and turnover;

hypothalamic 5-HT ranked second in content, but turnover of
5-HT was

ranked

seventh

(slowest).

The

hippocampus

was

ranked seventh in content and sixth in turnover for both DA
and 5-HT. However, the effect of 3-CSAL does not seem to be
attributable

to

increased

synthesis

since

5-HTP did not

accumulate above control levels when its decarboxylation was
inhibited.

Table 34
A SUMMARY OF RANK OF SEVEN BRAIN TISSUES BY BOTH
NEUROTRANSMITTER CONTENT AND TURNOVER
SEROTONIN
CONTENT
TURNOVER

TISSUE

DOPAMINE
CONTENT
TURNOVER

CEREBRAL-CORTEX

5

5

3

3

DIENCEPHALON

2

7

4

4

HIPPOCAMPUS

7

6

7

6(a)

MESENCEPHALON

3

1

6

6(a)

PONS-MEDULLA

1

4

5

5

STRIATUM

6

2(a)

1

1

TELENCEPHALON

4

2(a)

2

2

Rank of !=Highest; Rank of 7=Lowest
(a)=tie between the turnover rates for these two tissues.
Adapted from Smith et al. Prog. Neuro-Psychopharm. 2: 359-367 (1978).
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F. Acute 3-CSAL elevates striatal 5-HT
without consistently lowering 5-HIAA.

Acute

experiments

rather specific

with

effect upon

3-CSAL

have

demonstrated

the serotonin

content of

a

the

corpus striatum. Serotonin and 5-HIAA levels in the hypothalamus and hippocampus were unaffected at the one hour time
point

despite

the

fact

that

3-CSAL and

its

0-methylated

metabolites were present in these tissues. The effects of a
single 50

mg/kg dose of 3-CSAL was assessed

points of 30 minutes, 1, 3, 8,

at the

and 24 hours. Fig 22 shows

the percent relative concentrations of 5-HT and
these time points.

time

At the 30 minute time point,

5-HIAA at
5 -HT was

significantly elevated whereas 5-HIAA was unaffected.

This

would be consonant with increased synthesis of 5-HT. At the
one hour time point, both 5-HT and 5-HIAA were significantly
elevated,

but synthesis exceeded

catabolism,

as one might

see in the case of increased turnover. At three hours after
the dose was administered,
5-HIAA was
hours

of

not different

time,

the

5-HT was
from

levels

the

of both

further elevated but
control
5-HT

levels.

By

24

and 5-HIAA were

returned to the normal range.
The eight hour maximal effect upon striatal 5-HT does
not correlate with the levels of the 3-CSAL, which is nearly
undetectable at this time.

This fact raises the possibility
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that

unanalyzed

metabolites

of

3-CSAL were

present

and

affected the 5-HT system.
Quipazine is a drug which increases whole brain 5-HT.
Medon et al (93) found that quipazine was a potent blocker
of

5-HT

uptake.

increased

whole

Jacoby
brain

et

al

5-HT

(94)

levels

saw

that

while

quipazine

significantly

decreasing 5-HIAA by 35% one hour post a 10 mg/kg injection.
Regionally, the striatum was the least sensitive to quipazine effects whereas the greatest activity was seen in the
hypothalamus.

This

is

the converse

of 3-CSAL' s

regional

effects. Fuller et al (95) documented the effects of quipazine

on

serotonin

metabolism

in

rat

brain.

Quipazine

decreased 5-hydroxytryptophan accumulation when the total
aromatic amino
given.

acid decarboxylase

inhibitor

NSD-1015 was

Thus the increase in 5-HT was not due to MAO inhib-

ition but rather by the fact that quipazine acts as a serotonin receptor agonist. The results of the synthesis experiment suggests that 3-CSAL acts in the same way.
Ho et al (96) investigated the mechanism of serotonin
elevation by 6-methoxy-THBC. This compound exerted no effect
upon mouse brain tryptophan hydroxylase. 6-methoxy-THBC did,
however, produce a significant facilitation of labeled 5-HTP
uptake into mouse brain.

In another publication, Ho et al

(97) stated that 6-methoxy-THBC did not affect norepineph-
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rine

levels

unchanged,

but

did

alter

5-HT

levels.

Since

NE

was

they speculated that the 5-HT increase was not

due to the inhibition of MAO activity.
tionation

studies

in

mouse

brain

Subcellular frac-

showed

a

significant

increase in the particulate fraction of "bound" 5-HT.

The

6-methoxy-THBC slowed the disappearance of intracisternally
injected labeled 5-HT, but had no effect upon the levels of
5-HIAA.
nism

Increased binding of 5-HT was suggested as a mecha-

for

the

brain 5-HT.

effect

of

6-methoxy-THBC' s

Shields and Eccleston

"protection"

of

(98) have offered evi-

dence for the synthesis and storage of 5-HT in two separate
pools in the brain. In their experiment, animals were given
labeled tryptophan followed by LSD, which decreases the firing rate of 5-HT neurons.
labeled tryptophan

to

They found that the conversion of

labeled

5-HT

was

changed,

but

the

overall rate of 5-HT formation was not changed. 5-HT formed
from

tryptophan was

called the

functional

pool

of

5-HT,

whereas the other 5-HT formed was called the reserve pool of
5-HT.

When DDC was totally inhibited, 3-CSAL still elevated

5-HT. Thus if increased synthesis was the source of the elevated 5-HT, the 5-HT must be coming from the "reserve pool".
It

is

speculated that

fraction

of

metabolism.

5-HT,

perhaps 3-CSAL

protecting

the

increases the

neurotransmitter

bound
from

However, further studies would be necessary to

answer this question.
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G. The relationship of age to the effect
of 3-CSAL on 5-HT.
The weight gain with respect to age for Sprague-Dawley rats
on normal rations is shown in Figure 23. By 35 days of age
the rats are fertile.

At King Animal Laboratories (Madison,

Wise.) breeding begins at 42 days of age (6 weeks). The typical weights for these animals are 125-150g for the females
and 150-175g for the males. More success in breeding is seen
in 63 day old rats (9 weeks). Typically, these females weigh
175-200g and the males weigh 225-250g.
Proven breeders are animals which have raised two consecutive litters to the age of weaning. However if an animal
fails to continue to produce litters it becomes a retired
breeder; typically females are retired by King by 6-8 months
of age; males

are retired at 8-10 months of age.

By 9

months of age the estrous cycle in the female becomes prolonged and with further aging the animal becomes anestrous.
Considering the fact that the life expectancy of a rat can
be up to 36 months, retired breeders have only lived 25% of
their life expectancy and yet they have clearly aged.
CNS of the rat does not

The

achieve developmental maturation

until 2 months of age (99). The levels of dopamine, dopamine
sensitive adenyl cyclase, synaptosomal dopamine uptake and
tyrosine hydroxylase are stable between 2-12 months of age.

Figure 23:

The relationship of age to gram weight in male Sprague-Dawley rats.
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After this time dopamine levels, receptors, tyrosine hydroxylase levels, and dopamine sensitive adenyl cyclase levels
decline.
Vasko et al.

(100) have measured steady state levels

of brain acetylcholine in young (28 days), adult (90 days),
and old (24 months) male Holtzman rats.

Despite the fact

that there was no difference in steady state brain control
levels of acetylcholine, Vasko found marked changes in brain
acetylcholine in response to d-amphetamine in young and old
rats, but not in the adults. Timiras (101) found that choline acetyltransferase

activity does not

change markedly

from 2-12 months in rat cerebellum and cerebral hemispheres.
But choline acetyltransferase activity in the spinal cord
decreased significantly with age.
Both young and mature male Sprague-Dawley rats showed
a significant increase in striatal 5-HT 8 hours after 3-CSAL
was administered. However this effect was not seen in older
rats.

It

is

possible

to

speculate that

the

differences

between groups could be related either to a loss of neurons
due to aging, a reduced regional blood flow, an age related
altering of metabolic pathways, or to altered 5-HT turnover.
Marquis

et al

(102)

have

demonstrated dopamine

alterations in aging mouse and rat

receptor

striatum. Cubells and

Joseph (103) also have shown an age related DA receptor loss
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in rats. Samorajski (104) has demonstrated decreased striatal DA synthesis in older rats. Synaptosomal DA uptake is
reduced in hypothalamic and striatal synaptosomes of aged
mice (105).

Striatal adenyl cyclase activity is signifi-

cantly lower in aged mice (106,107) and rabbits (108).
dopamine

content of

decreased

in older

the human
subjects

striatum is

(109,110).

Also

significantly

It is

not

clear

whether the DA neurons per se or their metabolic abilities
are required for 3-CSAL's effect upon striatal 5-HT.
Ohata et al (111) have shown that there is no significant difference in striatal or hypothalamic blood flow in
rats at the ages investigated.

Therefore the difference in

5-HT effect seen is not related to perfusion.

It is possi-

ble that relative competency of peripheral drug metabolism
by the liver could account for the change in effect with
respect to age.

For example, Macklon et al (112) have shown

that older patients are not able to metabolize diazepam as
quickly as younger adults.

Also, the lean mass or relative

percent body fat could be different between groups.

With

more body fat, a fat soluble drug may not realize the same
brain drug levels as a lean animal would. The exact reason
for the lack of an 8 hour effect of acute 3-CSAL is not
readily clear, but it is reproducible.
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H. Chronic 3-CSAL reduces 5-HT in both
the striatum and the hypothalamus.
The

acute

studies

consistently

demonstrated

increase in striatal 5 -HT levels. However,

an

chronic 3-CSAL

administration significantly depleted striatal 5-HT to 48%
of the control values. Tryptophan, the precursor amino acid
for 5-HT, was significantly elevated in the striatal tissue
of the experimental animals. However, striatal 5-HIAA levels
were not significantly different between the groups.
Chronic 3-CSAL also produced a significant depletion
of 5-HT in the hypothalamus. Hypothalamic tryptophan was not
significantly different between groups but 5-HIAA was significantly depleted.

The fact

that a hypothalamic effect

was seen chronically but not at the one hour time point
could well be related to the fact that 5-HT turnover is very
slow in the hypothalamus.
The mechanism of the 5-HT depletion by chronic 3-CSAL
is unclear as are the effects of other THIQs upon the serotonergic system which have been reported in the literature.
Livrea (113) saw a paradoxical change in the serotonergic
system's response to THP when acutely or chronically administered. When THP was given acutely at a dose of 60 mg/kg, 2
hours post injection 5-HIAA was significantly elevated. This
elevation was short lived in that 5-HIAA levels returned to
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normal at 4 hours post injection and remained so when further checked at 6 and 12 hours post injection.

Chronic THP

(8 mg/kg) significantly lowered 5-HIAA levels.

Livrea con-

cluded that this was a result of decreased turnover. Another
explanation

however

is

that

this

decrease

could

have

resulted from a toxic effect upon serotonergic neurons. Similar to the neurotoxicity of 3-CSAL is the neurotoxicity of
halogenated phenethylamines and amphetamines. Chronic doses
of these drugs cause marked depletion of 5-HT(ll4-121).
It is unknown whether or not 3-CSAL is taken up into
serotonin nerve endings. It is known however that the depletion of 5-HT by 1-Dopa is independent of uptake into 5-HT
neurons by the serotonin pump (122).
this question is to

One approach to answer

lesion the 5-HT system of rats with

5, 7-dihydroxytryptamine followed by 3-CSAL administration.
The resultant

levels and disappearance of 3-CSAL and its

mono-0-methyl metabolites could be measured in all 7 of the
brain regions described by Smith et al and compared to control

levels.

A

low

accumulation

of

3-CSAL

in

5, 7 -dihydroxytryptamine lesioned animals may indicate the
necessity of uptake of the THIQs into the serotonergic nerve
endings for the effects upon the serotonergic system to be
seen.

When followed by experiments which block uptake into

the serotonergic system by the serotonin pump, it would be
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possible to define if 3-CSAL uptake into serotonergic neurons is necessary for the increase of 5-HT to be seen.

I. 3-CSAL after pretreatment with decarboxylase
inhibitors elevates 5-HT and 5-HIAA is
unchanged or lowered.
When a peripheral DDC

inhibitor was

given prior to

3-CSAL, striatal 5-HT was elevated 3 fold compared to controls whereas 5-HIAA levels were unchanged.

For both the

hippocampus and hypothalamus neither 5-HT nor 5-HIAA levels
were altered despite the fact that 3-CSAL and its mono-0-methyl metabolites were present in these tissues.

It is not

yet known if 5-HT content in these brain regions would be
affected at other time points. It is known however that of
the tissues analyzed, 5-HT turnover is fastest in the caudate.
Also, animals pretreated with the total decarboxylase
inhibitor followed by 3-CSAL had significantly elevated 5-HT
levels and lower 5-HIAA levels in the striatum. Hypothalamic
5-HT was

elevated with this treatment,

but 5-HIAA levels

were decreased. Neither 5-HT nor 5-HIAA levels were altered
in the hippocampus.

In none of the experiments has there

been a hippocampal 5-HT effect although 3-CSAL levels are
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detected in this tissue.

The increases in 5-HT by 3-CSAL

seen when decarboxylase inhibitors were given could be due
to

MAO inhibition,

activity

as

a serotonin

facilitated 5-HT turnover and uptake.

agonist,

or

The increases in ser-

otonin seen were similiar to the MAO inhibition by beta-carbolines described by Ho et al

(97). Meyerson et al

(123)

demonstrated that MAO A, the 5-HT specific oxidase, was more
sensitive to inhibition by isoquinolines than was MAO B.
The hypothalamic changes seen with the total decarboxylase
inhibitor resemble MAO inhibition.

However, other experi-

ments indicate that 3-CSAL does not inhibit MAO in vivo (Dr.
Collins; personal communication). Thus there is a synergistic action of NSD-1015 and 3-CSAL which resembles MAO inhibit ion.

J. Other carboxylated THIQs studied also
alter brain serotonin content.
Acute 1-CSAL i.p. significantly elevated both 5-HT and
5-HIAA in the striatum. In another brain area, the hypothalamus, however, 1-CSAL appeared to increase 5-HT turnover at
one hour, as suggested by the elevated 5-HIAA levels with
no change in 5-HT levels.

Origitano

(91)

found similiar

results in the hypothalamus when 1-CSAL was given intraventricularly.
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It is of interest to note that the 5-HT and 5-HIAA
levels were increased in the striatum for both of the geometric isomers of carboxylated-SAL.

This could indicate a

similiar mechanism of action in the striatum.

The 3-carboxy

isomer however achieved significantly higher brain levels
than did the 1-carboxy isomer. The hypothalamic effect of
1-CSAL was dissimiliar to the 3-carboxy isomer. In none of
the experiments

with 3-CSAL as

the sole drug

given was

5-HIAA elevated in the hypothalamus.
There was no effect of 1-CSAL upon hippocampal 5-HT or
5-HIAA levels at the time point examined despite the fact
that tissue levels of 1-CSAL were seen.

In contrast, when

the 1-CSAL was given intraventricularly, (Origitano (91)),
an increase in hippocampal 5-HIAA was seen. The differences
in these results may lie in the dose and route of administration.

Another explanation for the increased hippocampal

5-HIAA could be due to displacement of 5-HT stores. Uptake
and release of THIQs

have been described by Cohen et al

(124), but they did not examine carboxylated THIQs.
Peripherally administered 1-carboxy-THP significantly
elevated 5-HT and 5-HIAA in the striatum. The hippocampal
and hypothalamic 5-HT and 5-HIAA content were unaffected.
The levels of 1-carboxy-THP were the highest in the hypothalamus and yet there was no serotonergic effect in that tissue at this one hour time point.
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K. 3-CSAL does not alter DA levels.
Acute 3-CSAL treatment had no effect upon striatal DA
or hypothalamic DA or NE content. Increasing the dosage of
3-CSAL also had no effect upon striatal DA content, furthermore chronic exposure to 3-CSAL (5 days) had no effect upon
striatal DA or hypothalamic NE or DA.
When the acid metabolites of DA (HVA and DaPAC) were
analyzed,

it could be seen that DA turnover was probably

increased by acutely administered 3-CSAL.
single-dose/time course

The data from the

experiment revealed that

levels were significantly lowered at

the HVA

the 30 minute time

point. This was probably due to the fact that 3-CSAL was
competing with DaPAC or DA for the enzyme caMT. At the one
and three hour time points HVA levels had returned to normal, suggesting either that 3-CSAL was mostly a-methylated
by this

time or that some compensatory mechanism was

in

effect. At the eight hour time point, the HVA levels were
significantly elevated over the control levels.

Remembering

that DA levels were not different than those for the controls, one can conclude that DA turnover has been accelerated.

HVA levels were further elevated at the 24 hour time

point, which suggests that dopaminergic activity was still
elevated despite the fact that neither 3-CSAL nor its a-methylated metabolites were detected in the tissues at the 24
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hour time point.

Again, the possibility that other metabo-

lites of 3-CSAL were active at these time points must be
considered.
The striatal DOPAC levels were not significantly different for the controls at the 30 minute time point. Nonstatistical increases in DOPAC levels were seen at the one
and three hour time points. A statistically significant elevation in DOPAC levels were seen at the 8 and 24 hour time
points. These results concur with the theory of increased
dopaminergic activity in the corpus striatum. More precise
information could be gained using radiolabeled 1-dopa to
follow the turnover of DA when 3-CSAL is given.

L. 3-CSAL and DDC inhibitors lower DA levels in rats.
Striatal

DA

was

significantly

depleted

in

3-CSAL

treated animals pretreated with R04-4602 such that peripheral DDC was inhibited.

In this experiment striatal DOPAC

levels were significantly decreased when compared to controls.

However HVA levels were no different between groups.

These results suggest that DA turnover was not increased by
3-CSAL.
When 3-CSAL was preceded by total decarboxylase inhibiton

by

NSD-1015,

DA

levels

also

were

significantly
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depleted. This drug combination produced striatal DOPAC levels which were significantly lower compared to the controls.
Thus 3-CSAL produced lower DOPAC

levels when DDC was

either peripherally or totally inhibited. The decarboxylase
inhibitors

prevented the

replenishment of

DA and

subse-

quently its acid metabolites.
No 3-CSAL hypothalamic effect upon the dopaminergic
system was seen in animals pretreated with peripheral DDC
inhibitor, but central DDC inhibition in tandem with 3-CSAL
did produce a hypothalamic dopaminergic effect; there was no
decrease in dopamine levels, but DOPAC levels were significantly elevated for the experimental group.

These findings

suggest an increased DA turnover as a real effect of 3-CSAL.
However, the possibility of increased turnover requires verification by an alternate method.

M. Other carboxylated THIQs and DA levels.
1-CSAL affected the striatal dopaminergic system, as
seen by statistically increased HVA levels in the experimental group. There was, however, no difference in striatal DA
and DOPAC levels between the experimental and control
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groups. Thus in the striatum either turnover was increased
or

1-CSAL competed with HVA for

Origitano

(91)

found

that

egress from the system.

1-CSAL

intraventricularly had

increased striatal HVA and DOPAC but had no effect on DA.
The lack of agreement between these results must be viewed
in light of the differences in dose and route of administration.
The hypothalamic dopaminergic system was affected by
1-CSAL in a different way. Hypothalamic dopamine as well as
DOPAC was significantly elevated when compared to controls.
HVA levels however were not altered.

Thus it appeared that

peripheral 1-CSAL increased the synthesis and turnover of
DA. Central 1-CSAL (91) had no effect on DA or HVA and significantly decreased hypothalamic DOPAC content. Again,

it

is interesting to note the differences in results from the
central versus peripheral administration
In the striatum DA levels were unaffected by acute
1-carboxy-THP; DOPAC levels also were unchanged; only striatal HVA was

elevated,

increased DA turnover

Again,
or

a

this was

either due to an

decreased egression of

HVA.

Whereas 1-CSAL had an effect upon the hypothalamic dopaminergic system, 1-carboxy-THP had no effect upon any of the
components of the hypothalamic dopaminergic system assayed.
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The effects of the carboxylated THIQs on DA systems
can be compared to the effects of non -carboxylated THIQs.
When Livrea et al (113) administered THP acutely, levels of
HVA in rat brain first

increased at 2 hours post dose,

decreased by 4 hours, and returned to normal at 6 to 12
hours. The acute changes were explained as aDA displacement
and HVA elevation followed by DA and HVA depletion. This was
subsequently

followed

by

recovery.

When THP

was

given

chronically, the Livrea group saw that HVA levels 12 hours
after the final dose were no different than that for the
control

groups.

Awazi

and Guldberg

( 125)

reported

that

striatal DA levels were unaffected 3 hours after a centrally
administered 10 ug dose of THP.
70 to 250 ug

Paradoxically, THP doses of

resulted in lower DA levels.

In separate experiments SAL and THP have been given
intraventricularly to rats in "physiological doses" acutely
(126).

Low doses of SAL (40-200 ng) produced no significant

change in catecholamine levels in the pons or striatum.
Awazi and Guldberg

(125) found that after a 250 ug

dose of SAL striatal DA was elevated

5 to 6 hours later,

and diencephalic NE content was reduced significantly. Haloperidol, the DA receptor antagonist blocked the SAL induced
changes in the DA contents. Thus this THIQ and others may
well interact with DA receptors.
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It appears that all of the THIQs investigated affect
the turnover of DA.

It would be of great interest to see in

future

if

experiments

antagonists

block the

haloperidol
effects of

or

other

DA

receptor

the carboxylated THIQs

reported in this dissertation.

N. Central interactions between dopaminergic
and serotonergic systems.
Since

3-CSAL has

been demonstrated

to affect

both

dopamine turnover and 5-HT levels in the corpus striatum, it
is fitting to speculate that these facts
Researchers

have

demonstrated

may be related.

interactions

between

the

dopaminergic and serotonergic systems of the central nervous
system. For example, 5-HT is involved in the 1-dopa induced
cortical synchronization in the rabbit

(127).

Unilateral

nigrostriatal lesions in rats followed by apomorphine produces contralateral turning responses and stereo-typic gnawing (128).
cantly

The rate of contralateral turning was signifi-

decreased

by

pretreatment

with

5-HTP.

The

effectiveness of apomorphine induced turning was enhanced by
depletion of 5-HT by p-chlorophenylalanine or by blockade of
5-HT receptors by methysergide.
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Serotonin appears to diminish many aspects of behavioral

arousal.

When 5-HT is depleted by p-chloro-phenyl-

alanine locomotion in response to 1-dopa is increased (129).
Green (130) has seen an enhancement of amphetamine action
after

interruption

of ascending serotonergic

electrolytic lesions.

pathways by

The inhibitory function of 5-HT is

reinforced by the fact that the threshold dosage of amphetamine required to elicit stereotypic behavior in the guinea
pig are decreased by methysergide and increased by 5-HTP.
Also, 5-HTP reverses abnormal jaw, mouth and other movements
produced by 1-dopa in monkeys with tegmental lesions (132).
Amphetamine induced locomotion and stereotypy are significantly elevated after p-chlorophenylalanine pretreatment of
rats (133). The 1-dopa induced emission of seminal fluid has
been shown to be mediated through 5-HT mechanisms (134).

0. Interactions between DDC inhibitors and 3-CSAL
Both

peripheral

and

total

decarboxylase

inhibition

followed by 3-CSAL resulted in significantly elevated striatal 5-HT and significantly depleted striatal DA. The common
factor

between

NSD-1015

and R04-4602

is

that

the

both

inhibit peripheral decarboxylation. This leads to elevated
serum levels of 1-dopa and tryptophan. If peripheral decar-
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boxylase inhibition results in decreased striatal levels of
tyrosine then a mild inhibitor of tyrosine hydroxylase could
significantly reduce dopamine levels.

P. Behavioral effects of 3-CSAL.
Known behavioral effects of 3-CSAL are analgesia (38)
and potentiation of ethanol induced narcosis (36). It is a
distinct possibility that these effects are mediated through
3-CSAL' s effect upon 5-HT. Fibiger et al.
that

animals

pretreated with

the

(135) have shown

tryptophan

hydroxylase

inhibitor p-chloro-phenylalanine were more reactive to electro-shock.

This sensitivity could be reversed by injecting

the animals with 5-HTP.

Fluoxitine, which inhibits the ser-

otonin-amine pump, has been shown to produce analgesia in
rats

receiving

electro-shock

(136).

Fluoxitine

also

reverses the p-chloro-phenylalanine induced hyperalgia. Quipazine, which is a serotonin receptor agonist produces analgesia in rats tested by the hot plate method (137).
The dorsal raphe nucleus sends 5-HT projections to the
pontine recticular formation. Jouvet (138,139) has provided
evidence that the serotonergic system is

involved in the

sleep process. Elevating 5-HT in the pontine recticular formation prolongs deep sleep. The work of this dissertation
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has shown 5-HT to be elevated in the striatum, one could
speculate then that the potentiation of ethanol induced narcosis by 3-CSAL could be through elevated pontine recticular

5-HT.

CHAPTER VI
SUMMARY

3-CSAL was used as a test alkaloid to see if carboxylated THIQs are decarboxylated in vivo in a rat model. When
given intraperitoneally,

large amounts of 3-CSAL and its

mono-a-methyl metabolites were taken up into the brain. In
contrast,

SAL itself when given i.p.

does not enter the

brain to any appreciable extent due to the blood brain barrier(39).

No appreciable decarboxylation of 3-CSAL or its

mono-a-methyl metabolites to THIQs was seen in any of the
tissues analyzed

( <1%).

The oxidative decarboxylation of

3-CSAL to DHIQs was also found to be negligable (<1%).
In contrast to other THIQs such as SAL, 1-CSAL, and
THP which are stereospecifically a-methylated, 3-CSAL was
mono-a-methylated to an equivalent extent on both available
hydroxyls of the ring.

Despite the fact that serum levels

of the two a-methylated isomers of 3-CSAL were essentially
the same, tissue levels of the 6-M-isomer were consistently
higher

than

the

7-M-isomer.

It

is

speculated

that

the

7-M-isomer has a meta- hydroxyl available for conjugation or
sulfation which would lead to its more rapid clearance. The
6-M-isomer has the 7-hydroxyl remaining, but this site may
not be preferred for these reactions.
169
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Levels of THIQs were highest when no inhibitor of DDC
were given. It is possible that 1-dopa and 5-HTP which accumulate

with

the

decarboxylase

pretreatment

compete

with

3-CSAL and its mono-0-methylated metabolites for uptake into
the brain.

Levels of the THIQs were consistently highest in

the hypothalamus which has the greatest serotonergic innervation of any of the tissues analyzed. It is suggested that
carboxylated THIQs may be preferentially taken up into serotonergic neurons.
Summaries of the effects of 3-CSAL upon the dopaminergic system and serotonergic systems are provided in Tables
35 and 36 respectively.

These two tables state the changes

in the levels of the particular neurotransmitters and their
acid metabolite(s) with respect to the various experimental
conditions examined.

Increases are depicted by the upward

arrow; decreases by the downward arrow; and no significant
difference by the horizontal arrow.
Levels of DA were relatively unaffected by carboxylated-THIQs unless animals were pretreated with decarboxylase
inhibitors. Turnover of DA appears to be increased by carboxylated-THIQs in certain brain regions, but the significance of the mild dopaminergic effect is not understood at
this time.

Table 35
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A SUMMARY OF CARBOXYLATED-THIQs EFFECTS UPON
THE STRIATAL DOPAMINERGIC SYSTEM
CONDITION

DA

DOPAC

....

-+

HVA

ACUTE 3-CSAL
30 Min.

.....

....

t
t

f
f

~

l

.....

-+

3 Hr.

-+

Hr.

-+

24 Hr.

8

R04-4602 and
Acute 3-CSAL

....

....
....

Hr.

1

l

NSD-1015 and
Acute 3-CSAL
Chronic 3-CSAL

t

1-CSAL
1-Carboxy-THP

-+

f
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Table 36
A SUMMARY OF CARBOXYLATED-THIQs EFFECTS
UPON STRIATAL 5-HT and 5-HIAA
CONDITION

5-HT

ACUTE 3-CSAL
30 Min.
1 Hr.
3 Hr.
8 Hr.
24 Hr.
R04-4602 and
Acute 3-CSAL

5-HIAA

_.

f
f

t

+
+

+

...

_.

t

t

NSD-1015 and
Acute 3-CSAL
Chronic 3-CSAL
1-CSAL

t

t

1-Carboxy-THP

+

t
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Despite the fact that the alkaloids are structurally
related to dopamine the carboxylated THIQs

examined here

have their most prominent effects on the serotonergic system.

The precise mechanisms underlying the elevations are

not certain. 3-CSAL is not a good inhibitor of MAO A but it
could be acting as a serotonin agonist or could be causing
increases in the amount of "bound" 5-HT.
Nevertheless, chronic 3-CSAL depletes the 5-HT content
of both the hypothalamic and striatal tissues of rats. The
nature of this deficit is unknown. It is possible that this
is a neurotoxic effect.

In support of this theory, Druse-

Manteuffel et at (140) have found that repeated injections
of DNLCA (the 1-carboxy-THIQ condensation product of DA and
phenylpyruvic acid), significantly reduced the striatal 5-HT
content of rat pups. More experiments need to be designed to
ascertain the mechanism of the 5-HT depletion and to determine if there is indeed a toxic effect of carboxylated-THIQs
on the serotonergic system.
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